Tumor specific antigens and uses thereof
IncRNA-derived peptides with strong MHC affinity are identified and used as tumor-specific antigens, addressing the need for new therapeutic approaches in multiple myeloma, offering a more precise and effective treatment by inducing a specific T-cell immune response.
Patent Information
- Application Number
- PCT/EP2024/062657
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-05-07
- Publication Date
- 2024-11-14
AI Technical Summary
Current cancer treatments for multiple myeloma, particularly those involving immunotherapies, rely on peptides from protein-coding genes, while there is a need for new therapeutic approaches targeting peptides from long noncoding RNAs (IncRNAs) due to the potential of IncRNAs to produce tumor-specific antigens not explored previously, especially in cancers with DIS3 mutations.
Identification and utilization of specific peptides derived from translated open reading frames (ORFs) in long noncoding RNAs (IncRNAs) that have a strong affinity for the MHC presentation system, using ribosome profiling and immunopeptidomic analysis to confirm their presence and tumor-specificity in multiple myeloma patients with DIS3 mutations.
The use of IncRNA-derived peptides as tumor-specific antigens provides a more precise and effective therapeutic target, inducing a specific T-cell immune response and potentially improving treatment outcomes for multiple myeloma and other cancers with DIS3 mutations.
Smart Images

Figure IMGF000013_0001 
Figure IMGF000014_0001 
Figure IMGF000014_0002
Abstract
Description
[0001] Tumor specific antigens and uses thereof
[0002] FIELD OF THE INVENTION
[0003] The present invention relates to the field of medicine, especially oncology. More particularly, the invention relates to tumor specific peptides derived from the translated ORF sequence in long noncoding RNA (IncRNA), and the uses thereof in cancer vaccines and cell therapy, in particular for the treatment of multiple myeloma.
[0004] BACKGROUND OF THE INVENTION
[0005] Long noncoding RNAs (IncRNAs) are a class of at least 200 nucleotide long transcripts that by first definition do not have a coding potential as messenger RNAs (mRNAs). Several lines of evidence suggest that IncRNA half-lives are shorter than mRNA. Degradation may be the crucial step that determines cellular abundance for at least some of IncRNAs. Similarly to mRNAs, IncRNAs are often produced by RNA Polymerase II, capped and poly adenylated. There are two main exonucleolytic pathways that degrade RNA, either in 5’ - 3’ or 3’ - 5’ direction. The 3’ - 5’ pathway in human has numerous catalytic enzymes with EXOSCIO enriched in the nucleolus, DIS3L and DIS3L2 in the cytoplasm and DIS3 that has more nuclear presence but can be also found in the cytosol. These enzymes associate with a multisubunit complex called exosome and degrade unspliced, incorrectly polyadenylated transcripts or products of endonucleolytic cleavage. DIS3L2 was shown to function independently from exosome complex and degrade RNAs via an oligouridylation- dependent pathway. The 5’ - 3’ exonucleases XRN2 and XRN1 are localized in the nucleus and cytoplasm, respectively. XRN2 is mostly responsible for co -transcriptional digestion of 3’ flanking region promoting transcription termination. XRN1 is involved in cytoplasmic mRNA surveillance where transcripts have to be deadenylated by PAN2-PAN3 and CCR4-NOT complexes, followed by 5 ’ cap removal before XRN 1 5 ’ end digestion. Cytoplasmic surveillance of mRNA is strongly coupled with translation and modulation of gene expression. Therefore, there are quality control pathways, which eliminate transcripts with premature stop codon (PTC) - Nonsense Mediated Decay (NMD) or transcripts with stalled ribosome -No-Go Decay (NGD) or lacking stop codon- non-stop decay (NSD) pathway. Both 3 ’-5’ and 5 ’-3’ nucleases are involved in the NMD and NGD to protect the cell from producing faulty proteins. XRN1 was also shown to be present in p-bodies- dynamic cytoplasmic organelles that where shown to store mRNAs and to a lesser extent IncRNAs, depending on their GC content and coding capacity. Moreover, DIS3L2 was shown to associate with XRN1 in RNA-dependent manner and both were found with polysomes, suggesting their complementary and coordinated action. Many mammalian IncRNAs never exit the nucleus where the exosome was shown to be a main actor in their degradation. In particular, the long intergenic noncoding RNAs (lincRNAs) could be regulated by the exosome as they were shown to be enriched in nucleoplasm and bound by nuclear exosome cofactors. The enhancer RNAs and antisense IncRNA stability was shown to be dependent on nuclear exosome. However, their regulation could depend on cellular context or be independent of DIS3 as another study did not report their significant enrichment in DIS3 catalytic mutants. Moreover, depletion of DIS3 or other components of the exosome core results in accumulation of class of unstable transcripts called PROMPTS (promoter upstream transcripts) that are resulting from bidirectional transcription. These data are in line with the early IncRNA stability analysis performed in mouse Neuro-2a cell line where the nuclear-localized IncRNAs were shown to be more likely unstable.
[0006] However, a certain fraction of IncRNAs have ubiquitous or cytosolic presence, that can be cell linedependent. The growing list of examples of IncRNAs with cytoplasmic function, underlines their importance in inferred pathways. The fact that IncRNAs can contain Open Reading Frames (ORFs) of variable lengths, together with other features of mRNAs suggest that, potentially, they could be translated. In fact, some cytoplasmic IncRNAs were shown to be bound by ribosomes. Furthermore, this hypothesis is supported by evidence of IncRNA-derived peptides in different cellular contexts. But some of those ORFs could be aberrant, thus they could undergo similar quality control pathways as cytoplasmic mRNAs and ribosome stalling could be an additional mechanism of control of IncRNA levels. In yeast, Xrnl deletion resulted in discovery of a class of unstable IncRNAs called XUTs- Xrnl -sensitive unstable transcripts. Recently, some of those XUTs were shown to be associated with ribosome and their stability increased when translation was inhibited. Among human IncRNAs, snoRNA host genes were presented to be NMD sensitive and GAS5 was shown to be directly associated with ribosomes. 3’-5’ nucleases might play a role in IncRNA decay as uridylation followed by DIS3L2 degradation was demonstrated for some lincRNAs. DIS3, even though mostly nuclear, was implicated in degradation of different oligo-adenylated transcripts in cytoplasm of human cells. However, many mechanisms of surveillance were assumed to be conserved from yeast and the previous studies in human cells did not focus to fully answer which of the exonucleases are the key enzymes regulating levels of cytoplasmic IncRNAs.
[0007] The ultimate proof of IncRNA translation is detection of specific IncRNA-derived peptide(s). In recent years multiple efforts were undertaken to detect peptides coming from IncRNA and circular RNA derived ORFs. Some of the already known IncRNA functional micro peptides have been reviewed (Wright et al. 2022). Often, the ORFs coming from IncRNA are much shorter (sORF) with less than 100 amino acids. Therefore in Mass Spectrometry analyses, the probability to detect spectra from more than one oligo peptide are low and different methods to increase the detection of sORFs have been designed for higher level of confidence concerning sORF peptidome data analysis (Slavoff et al. 2013; Othoum et al. 2020). Moreover, unstable transcripts where shown to bind to the Major Histocompatibility Complex I (MHO) (Apcher et al. 2011) and the human leukocyte antigen (HLA) purification increased detection of peptides from non- canonical ORFs (Chen et al. 2020). Recent data show more examples of IncRNA-derived novel tumor specific antigens (Chong et al. 2020; Ehx et al. 2021). Thus, it is highly relevant to answer the question which unstable cytoplasmic IncRNAs could be bound by ribosome and translated.
[0008] Multiple myeloma (MM) is a bone marrow cancer characterized by multiple chromosomal rearrangements and mutations in specific protein coding genes. MM represents around 1% (176 404) of all cancer cases worldwide (data from 2020, www.wcrf.org) and it has a five-year survival rate of 55% (www.cancer.net). Several drugs have shown activity in multiple myeloma (MM) and are available for clinical use. As a result, there are numerous regimens that use two or more of these drugs available for the treatment of newly diagnosed and refractory / relapsed MM. The major classes include alkylating agents (melphalan andcyclophosphamide), corticosteroids (dexamethasone and prednisone), immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib, andixazomib). The treatment paradigm in MM is evolving with the introduction of various immunotherapies using for example monoclonal antibodies or Antibody-Drug Conjugates (ADCs) best exemplified by belantamabmafodotin (BM). Some of chimeric antigen receptor (CAR) T cell therapy as well as specific vaccine using peptide were also proposed for the MM treatments, especially for patients with relapse refractory MM. However, all these approaches are based on peptides coming from protein coding genes.
[0009] DIS3 is one of the genes mutated in multiple myeloma and in a few other cancer types (Robinson et al. 2018; Pertesi et al. 2019; Boyle et al. 2020; Walker et al. 2018; White et al. 2018; WeiBbach et al. 2015). Recently, a specific IncRNA signature related to DIS3 mutations was proposed by Todoerti et al. 2022. However, the translation potential of the DISTs in MM and other cancers was not previously explored. Although considerable progress has been made in understanding the pathogenesis and treatments of MM, there is still a need for new and efficient therapeutic approaches against MM and other cancers involving various DIS3 mutations.
[0010] SUMMARY OF THE INVENTION
[0011] As alternative, the inventors have proposed as target for therapy specific peptides coming from short open reading frames in long noncoding RNAs (IncRNAs), and combinations thereof. Even though IncRNAs were thought to not code for proteins, recent advancements in the ribosome profiling (Ribo-seq) and mass spectrometry (MS) show evidence of their potential to produce (poly)peptides (Chen et al. 2020). LncRNAs can be very specifically expressed in different types of tissues and cancers (Carle varo-Fita et al. 2020) giving an alternative to antigens coming from ubiquitously expressed proteins for more precise targeted therapies.
[0012] In the present invention, the inventors identified open reading frames (ORFs) included in IncRNAs that are translated in cells with inactivated DIS 3. Among the translated ORF sequences, they identified peptides that have a very strong affinity for the Class 1 or 2 (MHC) presentation system defining tumor specific antigens (TSAs) to multiple myeloma patients. More particularly, in order to identify multiple myeloma specific antigens coming from these IncRNAs, the inventors used their Ribo-seq data collected in the DIS3- depleted cell line model developed by Davidson et al., 2019.
[0013] It has been shown previously that DIS3 is an exonuclease responsible for degradation of many noncoding RNAs (Szczepinska et al., 2015), but the inventors are first to show that, upon DIS3 depletion from the cells, the IncRNAs that are regulated by DIS3 can be found in cytoplasm, bound by ribosomes. It has particular relevance to MM, where around 10% of patients harbor mutations in DIS3 gene, that can impair its activity, leading to accumulation of different noncoding RNAs (Tomecki et al., 2014).
[0014] The inventors also confirmed by immunopeptidomic (IP) experiments the presence of tumor specific peptides in DIS3-depleted cells or MM cell lines with DIS3 mutations.
[0015] Increased number of pathways and exonucleases present in mammalian cells, make the estimation of importance of different enzymes in cytoplasmic IncRNAs decay a challenging task. Therefore, in this application, to reduce the compensation effect, the inventors used auxin-inducible degron system that enables rapid depletion of protein of interest (Natsume et al. 2016). Using cellular fractionation and RNA sequencing from cells depleted of hXRNl or DIS 3, the inventors showed that hXRNl has limited role in degradation of subset of IncRNAs while DIS3 degrades larger proportion of gencode annotated and nonannotated IncRNAs. The inventors have also performed ribosome profiling and immunopeptidomic analysis which show that some of DIS3-sensitive transcripts (DISTs) residing in cytoplasm are bound by ribosome and are translated. The data from in vitro model show that some of tested DISTs are also present in multiple myeloma patients with mutations in DIS3 gene and can be a source of new tumor specific antigens.
[0016] Additionally, based on the cohort of multiple myeloma (MM) patients in comparison to samples from healthy donors (Hdllein et al., 2020), the inventors showed a correlation between lower level of DIS3 in MM patients and higher expression of the DIS3-sensitive IncRNAs. The inventors have also identified several differentially expressed ORFs in those higher expressed IncRNA being a source of tumor specific peptides. The advantage of such tumor specific peptides over existing therapeutic targets comes from their higher cellular specificity.
[0017] The present invention thus provides novel tumor specific peptides and uses thereof in the treatment of a cancer.
[0018] A particular object of the present invention relates to a tumor specific peptide, or a fragment thereof, wherein said peptide is between 8 to 30 amino acids in length and: (i) is derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55, 56, 61 and 64-81, with the proviso that when said translated ORF sequence is SEQ ID NOs: 17, the tumor specific peptide derived from this ORF sequence is other than that of SEQ ID NO: 37; or (ii) comprises, essentially consists of, or consists of a sequence selected from the group consisting of SEQ ID NOs: 18-36, 58, 59, 62, 63 and 82-104.
[0019] Preferably, said peptide (i) is derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-3, 7, 17 and 64- 81, with the proviso that when said translated ORF sequence is SEQ ID NOs: 17, the tumor specific peptide derived from this ORF sequence is other than that of SEQ 37, preferably any of SEQ ID NOs: 1-3, 7 and 17; or (ii) comprises, essentially consists of, or consists of a sequence selected from the group consisting of SEQ ID NOs: 82-104, preferably SEQ ID NOs: 96-98, 101 and 102.
[0020] Another particular object of the invention relates to a combination or a multimeric antigen comprising at least two peptides, wherein said peptides are between 8 to 30 amino acids in length and: (i) are derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55-57, 61 and 64-81; and / or (ii) comprise, essentially consist of, or consist of a sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104.
[0021] Preferably, said combination or a multimeric antigen comprises peptides: (i) derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-3, 7, 17 and 64-81, more preferably any of SEQ ID NOs: 1-3, 7 and 17; and / or (ii) comprising, essentially consisting of, or consisting of a sequence selected from the group consisting of SEQ ID NOs: 82-104, more preferably SEQ ID NOs: 96-98, 101 and 102.
[0022] Another particular object of the invention relates to a combination or multimeric antigen comprising at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides as defined herein. The invention also relates to a recombinant vector comprising a nucleic acid coding for a peptide as defined herein or for the combination or multimeric antigen as defined herein, wherein the nucleic acid is optionally linked to a regulatory region.
[0023] The invention further relates to a host cell comprising a recombinant vector as defined herein.
[0024] The invention also relates to an antibody or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds a peptide as described herein.
[0025] The invention also relates to a nucleic acid coding for the antibody, TCR or CAR of the invention or to a vector comprising a nucleic acid coding for the antibody, TCR or CAR of the invention.
[0026] Another object of the invention relates to a recombinant immune cell that specifically binds to one or more peptides of the invention. The immune cell is preferably selected from a group consisting of a T cell, CD4+ T cell, CD8+ T cell, B cell, NK cell, NKT cell, monocyte and dendritic cell. Preferably, the immune cell is for use in cell therapy of cancer.
[0027] Another object of the invention relates to an immune cell which comprises a TCR or CAR as described herein, or a nucleic acid coding for TCR or CAR as described herein, or a vector comprising the nucleic acid coding for TCR or CAR as described herein.
[0028] Another object of the invention relates to a pharmaceutical composition comprising a peptide, a combination or a multimeric antigen of the invention, a nucleic acid coding for one or more peptides of the invention, a vector, a cell, an antibody, TCR, CAR, a nucleic acid coding for such antibody, TCR or CAR or a vector comprising the nucleic acid coding for such antibody, TCR or CAR, or a recombinant immune cell as described herein.
[0029] A particular object of the invention relates to a vaccine or immunogenic composition, comprising a peptide, nucleic acid, vector, cell, combination or multimeric antigen as described herein. Such vaccine or immunogenic composition is capable of inducing a specific T-cell immune response.
[0030] The invention also relates to a peptide, nucleic acid, vector, cell, combination or multimeric antigen as described herein, for use as a vaccine, in particular a vaccine for treating a cancer or for preventing cancer relapse.
[0031] It further relates to a pharmaceutical composition as described herein for use as a drug, especially for use in the treatment of a cancer or in the prevention of cancer relapse.
[0032] The peptides, pharmaceutical compositions and vaccines of the invention may be administered via any conventional route. The invention may be used in any mammal, particularly in human subjects. It is suitable to beat cancer or prevent cancer relapse, wherein the cancer is preferably selected from blood cancer (such as multiple myeloma (MM), acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), plasma cell leukemia (PCL), mantle cell lymphoma, B-cell lymphoblastic leukemia / lymphoma, diffuse large B-cell lymphoma, peripheral T- cell lymphoma), glioblastoma (such as conventional glioblastoma multiforme), glioma (such as high-grade glioma), anaplastic astrocytoma, ovarian cancer (such as high grade ovarian serous adenocarcinoma), uterine cancer (such as uterine corpus leiomyosarcoma), breast cancer (such as invasive breast carcinoma, breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast invasive lobular carcinoma), prostate adenocarcinoma, skin cancer (such as melanoma, superficial spreading melanoma (SSM), superficial spreading melanoma, cutaneous melanoma, acral lentiginous melanoma, Merkel cell carcinoma), lung cancer (such as non-small cell lung carcinoma, lung adenocarcinoma, small cell lung carcinoma), leiomyosarcoma, neuroendocrine tumor, neuroendocrine carcinoma, hepatocellular carcinoma, bladder urothelial carcinoma, gastrointestinal stromal tumor and small intestinal neuroendocrine tumor. Preferably, the cancer is multiple myeloma, and in particular multiple myeloma characterized by DIS3 gene deregulation such as DIS gene mutation or misexpression.
[0033] LEGENDS TO THE FIGURES
[0034] Figure 1. DIS3 depletion results in accumulation of higher number of transcripts falling into noncoding RNA class. A) Scheme presenting experimental design of auxin treatment for depletion of XRN1 or DIS3 from HCT116 cell line followed by cell fractionation and sequencing of cytoplasmic fraction. B) a Western blot control of auxin treatment and depletion of the tagged DIS3 protein. C) supervised heatmaps presenting a z-score of differentially expressed genes in comparison to controls and non-treated cells n=7644 for DIS3).
[0035] Figure 2. DISTs in cytoplasm can be bound by ribosomes and translated A) Scheme presenting experimental workflow for Ribo-sq experiment. B) and C) metagene from Ribo-seq coverage spanning 50nt before and after start and stop codons for highest expressed open reading frames detected in DIS3- AID+ condition for mRNA (n=13711) and upregulated IncRNAs (n=750) respectively. D) Venn diagram of actively translated ORF identified by ribotricer in IncRNAs. E) Box plot presenting the length of highest expressed ORFs of IncRNAs detected from Ribo-seq as actively translated from DISTs- eRNA (n=381) and IncRNAs (n=369) and non-differential IncRNA (n=982) and PCG (n=1599) that were also detected to be bound with ribosomes (two-sided t-test * p-value< 0.001). F) and G) Boxplots presenting the length of 5’UTR and 3’UTR respectively, of IncRNAs ORFs detected from Ribo-seq as actively translated from upregulated IncRNA in DIS3-AID cells after auxin- eRNA (n=381) and IncRNAs (n=369) are presented separately in comparison to non-differential IncRNA (n=982) and PCG (n=1599) that were also detected to be bound with ribosomes (two-sided t-test * p-value< 0.001). H) Boxplot of full transcript length based on division of DISTs on their level on polyA+ RNAseq- upregulated (n=1241), not up (n=3921), nondifferential in total RNA-seq IncRNA (n=7748) and PCG (n=2850) I) venn Diagram of 5162 upregulated DISTs with information about their detection in polyA+ RNAseq (at least 20 counts), conservation and detection as actively translated in Ribo-seq for samples of DIS3-AID cells after auxin.
[0036] Figure 3. DISTs are detected in multiple myeloma patients with DIS3 mutations A) Atomic model of the DIS3 structure (PDB 6D6Q)47displayed using USCF Chimera68. Position of mutation, listed in Table 4 are indicated on the structure, with the mutations affecting the structure marked in dark grey and mutation creating truncated protein labelled with diagonal lines. B) Venn diagram presenting overlap between DE results for upregulated IncRNAs from the DIS3-AID cell line after auxin and DE from healthy control against samples from patients with mutations in DIS3 gene and DE between patient with or without the DIS3-mutation. C) Supervised heatmap presenting a z-score of differentially expressed 61 IncRNAs containing ORFs that are upregulated in patients with gene DIS3 mutation. D) Schematic of immunopeptidomic experiment for detection of IncRNA derived peptides. E) Dot plot showing correlation between predicted retention time from DeelLC51on y-axis and detected retention time on the x-axis, the unique and multihit peptides coming from IncRNAs sORFs are marked in black and dark grey respectively. F) Spectra of the immunopeptide detected in IP on top panel and prediction based on the sequence on the bottom with Prosit HLA CID 2020 model, with an Error between the two spectra in the middle plotted using Universal Spectrum Explorer53. G) Heatmap of 90thpercentile expression (log 10 of TPM+1) of GTEx samples from healthy tissue together with samples from the MM cohort and healthy control. ORFs are ordered as in Table 1, x is used to mark the samples that the expression level is below the threshold white or light grey shaded according to expression level.
[0037] Figure 4. Venn diagram of the overlap between upregulated IncRNAs from the DIS3-AID cell line treated with auxin and MM cases with mutations in the DIS 3 gene in comparison to healthy donors.
[0038] Figure 5. Heatmap of 90thpercentile expression (loglO of TPM) of 23 TSA candidate DIST-ORFs of particular interest, selected from Ribo-seq analyses in GTEx samples from heathy tissues (at least 45 samples per tissue) together with bone marrow samples from the MM cohort (“MM”) and healthy donors (“Healthy”). “MM DIS3mut” refers to MM cases with DIS3 mutation.
[0039] Figure 6. Spectrum of a peptide (of SEQ ID NO: 37) from a IncRNA ORF detected in KMS26 cell line, identified by MS Fragger. Figure 7. Results presenting mean fluorescence intensity detected by FACS analysis of easYmer synthetic HLA complexes indicated in the graph, folded with either a positive control, a peptide of interest (of SEQ ID NO: 37: VIFSKVGSSAV), a peptide of SEQ ID NO: 105: FSKVGSSAV, or no peptide.
[0040] DETAILED DESCRIPTION
[0041] The present invention provides novel tumor specific peptides derived from the translated ORF sequences of long-non coding RNA (IncRNA), pharmaceutical compositions comprising such tumor specific peptides and uses thereof in cancer therapy.
[0042] Definitions
[0043] Unless otherwise defined herein, all scientific and technical terms used in connection with the present invention have the same meaning as commonly understood by one of ordinary skill in the art.
[0044] As used herein, the term “nucleic acid” refers to an oligonucleotide, nucleotide or polynucleotide. A nucleic acid molecule may include deoxyribonucleotides, ribonucleotides, modified nucleotides or nucleotide analogs in any combination. The nucleic acid according to the invention may be an isolated or purified nucleic acid. The nucleic acid can be DNA (e.g., cDNA), RNA (e.g. IncRNA), or a mixture thereof. The nucleic acid can be single-stranded or double-stranded or a mixture of the two. It can comprise modified nucleotides, comprising for example a modified bond, a modified purine or pyrimidine base, or a modified sugar. It can be prepared by any method known to one skilled in the art, including chemical synthesis, recombination, and mutagenesis. The nucleic acid according to the invention may be deduced from the sequence of the peptide according to the invention and codon usage may be adapted according to the host cell in which the nucleic acid shall be transcribed. These steps may be carried out according to methods well known to one of ordinary skill in the art and some of which are described in the reference manual Sambrook et al. (Sambrook J, Russell D (2001) Molecular cloning: a laboratory manual, Third Edition Cold Spring Harbor). In a particular aspect, the term “nucleic acid” includes any nucleic acid molecule comprising any ORF sequence from long noncoding RNA (IncRNA) according to the invention. The term “nucleic acid” also includes any nucleic acid coding for the tumor specific peptide as described herein, or coding for any antibody, antigen-binding fragment thereof, TCR or CAR as described herein.
[0045] A “long-non coding RNA” (long ncRNA or IncRNA) is generally referred as a non-coding RNA that is at least 200 nucleotides in length, and has typically a length / size between 200 nucleotides and 20 kb. In a particular aspect, the IncRNA according to the invention is DIS3-sensitive and its expression is increased in the cytoplasm of DIS 3 -defective cells. The term “an open reading frame” or “ORF” refers to the part of a reading frame that has the ability to be translated into a peptide. An ORF is a continuous stretch of codons that contain a start codon (usually AUG in terms of RNA) at a transcription starting site (TSS) and a stop codon (for example UAA, UAG or UGA). An ATG codon within the ORF or non-canonical start codon of the translation such as CTG, AGG, AAG, GTG, TTG, ATC, ATT, ACG, ATA (not necessarily the first) may indicate where translation starts. The transcription termination site is located after the ORF, beyond the translation stop codon. The term “ORF” also includes short ORFs (sORFs) that may lack the classical hallmarks of protein-coding genes but which can produce functional peptides. In a particular aspect, the term relates to sORFs in long non-coding RNAs (IncRNA) which may be translated to functional peptides, preferably tumor specific peptides. The sequence of the ORF encoding the peptide of the invention can be obtained from a genomic DNA source, a cDNA source, generated by PCR from a cDNA source or chemically synthesized.
[0046] The term "recombinant" as used herein with respect to a nucleic acid sequence means a polynucleotide molecule of genomic, cDNA, viral, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation, is not associated with all or a portion of the polynucleotide with which it is associated in nature. The term "recombinant" as used herein with respect to a peptide sequence means a peptidic molecule produced by expression of a recombinant polynucleotide. In general, the gene of interest is cloned and then expressed in transformed organisms, as described further below. The host organism expresses the foreign gene to produce the protein under expression conditions. The term "recombinant" as used herein with respect to a cell means that the cell comprises a recombinant peptide sequence.
[0047] The term “expression cassette” refers to a nucleic acid construct that contains all elements needed for selfexpression. Expression cassettes typically include a promoter operably linked to a transgene, a transcription termination signal, a ribosome binding site, and a translation termination signal. The expression cassette may be in the form of a self-replicable expression vector.
[0048] The term “operably linked” as used herein indicates that fragments are arranged to be operable during transcription from a promoter to a stop codon through an amino acid-encoding sequence.
[0049] The term “expression vector” or “vector” or “expression construct” as used herein refers to a DNA construct having a polynucleotide base sequence encoding a target peptide operably linked to a suitable regulatory sequence, so as to be capable of expressing the target peptide in a suitable host. The regulatory sequence may include a promoter capable of initiating transcription, any operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome -binding site, and a sequence regulating the termination of transcription and translation. The expression vector may be transformed into a suitable host, and then replicated or function regardless of a host genome. The “expression vector” as described herein may be a cassette, plasmid, cosmid, phage, phagemid, artificial chromosome or vector such as viral or non- viral vector. Viral vectors known for therapeutic purposes are adenoviruses, adeno-associated viruses (AAVs), lentiviruses, retroviruses, canarypox, etc. However, non-viral vectors can also be used such as for example transposon-based vector systems.
[0050] As used herein, the term “antigen” means any molecule that causes an immune response or is capable of being bound by an antibody or other antigen-binding molecule. The part of an antigen that is recognized by antibodies, B cells or T cells, is an epitope. An antigen can be endogenously expressed (i.e., expressed by genomic DNA), or it can be recombinantly expressed, or chemically synthesized, optionally in combination with one or more molecules or agents. Generally, the immune response caused by an antigen can involve either antibody production, or the activation of specific immunologically competent cells, or both. One of ordinary skill in the art will readily understand that any macromolecule including any protein or peptide as described herein, or any molecule comprising any of such proteins or peptides or any cell presenting such molecules, can serve as an antigen.
[0051] In a particular aspect, the term “antigen” designates a tumor specific antigen (in monomeric form) or a combination of at least two tumor specific antigens as described herein. In a particular embodiment, the term antigen also comprises recombinant, chimeric or multimeric antigens which are synthetic antigens produced by expression vectors comprising a nucleic acid coding for at least two different proteins or peptides, or a combination of such recombinant, chimeric or multimeric antigens. A multimeric antigen may be dimeric, trimeric, tetrameric, etc. A monomeric, multimeric, recombinant or chimeric antigen according to the invention, or a combination thereof, may be free or conjugated, optionally linked or mixed with other antigens, molecules, agents or carriers.
[0052] As used herein, the term “epitope” is the specific portion of an antigen typically bound by an antibody or T cell receptor.
[0053] The term “tumor specific peptide” or “tumor specific antigen” or “peptide”, in the context of the present invention, designates an isolated peptide or antigen which is specific for tumor cells, and not for any other cell. Typically, the tumor specific peptide comprises from 8 to 30 amino acids, preferably from 8 to 20 amino acids or from 8 to 15 amino acids, more preferably at least 8 amino acids. In a particular aspect, the tumor specific peptide according to the invention is derived from the translated ORF sequence from long noncoding RNA (IncRNA).
[0054] The term “tumor specific peptide derived from the translated ORF sequence from long noncoding RNA (IncRNA)” or “tumor specific peptide derived from IncRNA” designates a peptide comprising, essentially consisting in or consisting in a sequence of 8 to 30, 8 to 20 or 5 to 15 consecutive amino acids of the translated ORF sequence from long noncoding RNA (IncRNA). Preferably, said peptide strongly binds to MHC or HLA molecule of Class I or II or both.
[0055] The term “consists essentially of’ means that the peptide consists of said sequence, but it may also comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 substitutions, additions, deletions or a mixture thereof, preferably 1, 2, 3, 4 or 5 substitutions, additions, deletions or a mixture thereof, and in particular 1, 2 or 3 substitutions, additions, deletions or a mixture thereof. In particular, by the term “consisting essentially of’ it can be envisaged that the peptide may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acids at the N- and / or C terminal ends, preferably 1, 2, 3, 4 or 5 additional amino acids, and / or 1, 2 or 3 additional amino acids. Preferably, the number of substitutions, additions, deletions or a mixture thereof depends on the length of the sequence. For example, the percentage of substitutions, deletions, additions or a mixture thereof may be no more than 30%, preferably no more than 25%, more preferably no more than 10%. As used herein, the term “substitution” refers to the exchange of a single amino acid for another one in a peptide sequence; the term “deletion” refers to the removal of a single amino acid from a peptide sequence; the terms “insertion” and “addition” are equivalent and refer to the addition of a single amino acid in a peptide sequence.
[0056] Optionally, the term refers to a sequence comprising 1, 2, 3, 4 or 5 mutations (addition, deletion and / or substitution). In a particular aspect, it refers to a sequence comprising / including / having 1, 2 or 3 nucleotide single mutations at one or both ends of the sequence. In a very particular aspect, it refers to a sequence comprising / including / having (i) the addition of 1, 2 or 3 nucleotides at one or both ends of the sequence; (ii) the deletion of 1, 2 or 3 nucleotides at one or both ends of the sequence; or (iii) the substitution of 1, 2 or 3 nucleotides.
[0057] The term “substitution” as used herein denotes the replacement of one amino acid residue with another one chosen from the 20 naturally occurring standard amino acid residues, rare naturally occurring amino acid residues and unnatural amino acids. Preferably, the term “substitution” refers to the replacement of one amino acid residue with another one chosen from the 20 naturally occurring standard amino acid residues (G, P, A, V, L, I, M, C, F, Y, W, H, K, R, Q, N, E, D, S and T). The substitution(s) may be conservative or non-conservative substitutions. As used herein, the term “conservative substitution” refers to a replacement of one amino acid residue with another one which has similar chemical or physical properties (size, charge or polarity). Examples of conservative substitutions are shown in the following tables.
[0058] [Table A]
[0059] [Table B]
[0060] [Table C]
[0061] As used herein, the term “sequence identity” or “identity” refers to the number (%) of pairs (identical amino acid residues) at positions from an alignment of two polypeptide sequences. Sequence identity is determined by comparing the sequences when they are aligned so as to maximize the overlap and identity while at the same time minimizing the sequence breaks. In particular, sequence identity can be determined using any of a number of global or local alignment algorithms, depending on the length of the two sequences. Sequences of similar lengths are preferably aligned using global alignment algorithms (e.g. Needleman & Wunsch, J. Mol. Biol 48:443, 1970) which optimally align the sequences along the entire length, whereas sequences of substantially different lengths are preferably aligned using a local alignment algorithm, for example the Smith-Waterman algorithm (Smith and Waterman, Adv. Appl. Math. 2:482, 1981) or the Altschul algorithm (Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402; Altschul et al. (2005) FEBS J. 272:5101-5109). Alignment for the purpose of determining the percentage of amino acid sequence identity can be performed via any method known to those skilled in the art, for example using software available on websites such as http: / / blast.ncbi.nlm. nih.gov / or http: / / www.ebi.ac.uk / Tools / emboss / . A person skilled in the art can readily determine the appropriate parameters for measuring alignment. For purposes of the present invention, the amino acid sequence identity percentage values refer to values generated using the EMBOSS Needle pairwise sequence alignment program which creates an optimum global alignment of two sequences using the Needleman-Wunsch algorithm in which the parameters are the default parameters: Scoring matrix = BLOSUM62, Gap open = 10, Gap extend = 0.5, End gap penalty = false, End gap open = 10 and End gap extend = 0.5.
[0062] The terms “derived” and “fragment”, in relation to peptides or ORFs, designate preferably an immunogenic fragment of a peptide or an ORF, retaining a capacity to induce or stimulate an immune response, preferably against the peptide. The immune response may be a cellular or antibody response. The immunogenic fragment of a peptide or an ORF is also capable of binding a MHC or HLA molecule of Class I and / or II.
[0063] The term “immunogenic” as used herein refers to the ability to elicit an immune response, for example via T cells, B cells or both.
[0064] The term "cancer" or “tumor”, as used herein, is defined as disease in which a group of cells display uncontrolled growth (division beyond the normal limits) and / or invasion (local intrusion and destruction of adjacent tissues) and / or metastasis (spread to other parts of the body via lymph or blood). This term includes any cancer type at any stage in any type of subject. This term also comprises cancer metastases and / or relapse of cancer. Preferably, the term “cancer” includes a cancer associated with an alteration of the DIS3 gene. Typically, cancer, as used herein, comprises blood cancer (such as multiple myeloma, acute myeloid leukaemia, chronic myelomonocytic leukaemia, chronic lymphocytic leukaemia, small lymphocytic lymphoma, plasma cell leukemia, mantle cell lymphoma, B-cell lymphoblastic leukemia / lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma), glioblastoma (such as conventional glioblastoma multiforme), glioma (such as high-grade glioma), anaplastic astrocytoma, ovarian cancer (such as high grade ovarian serous adenocarcinoma), uterine cancer (such as uterine corpus leiomyosarcoma), breast cancer (such as invasive breast carcinoma, breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast invasive lobular carcinoma), prostate adenocarcinoma, skin cancer (such as melanoma, superficial spreading melanoma, cutaneous melanoma, acral lentiginous melanoma, Merkel cell carcinoma), lung cancer (such as non-small cell lung carcinoma, lung adenocarcinoma, small cell lung carcinoma), leiomyosarcoma, neuroendocrine tumor, neuroendocrine carcinoma, hepatocellular carcinoma, bladder urothelial carcinoma, gastrointestinal stromal tumor and small intestinal neuroendocrine tumor. In a particular aspect, the term “cancer” encompasses multiple myeloma at any stage of progression, and preferably multiple myeloma characterized by DIS3 gene deregulation such as DIS3 mutation or misexpression.
[0065] A “relapse” or “recurrence” occurs when subjects are affected again by a cancer that affected them in the past. For example, if a patient has suffered from a cancer, has received a successful treatment of said cancer and again develops said cancer, said newly developed cancer may be considered as relapse or recurrence. However, a relapse or recurrence of a tumor may but does not necessarily occur at the site of the original tumor. A relapse or recurrence of a tumor also includes situations wherein a tumor occurs at a site different to the site of the original tumor as well as at the site of the original tumor.
[0066] As used herein, the term “treatment”, “treat” or “treating” refers to any act intended to ameliorate the health status of patients such as therapy, prevention, prophylaxis and retardation of the cancer or of at least one symptom of the cancer. It designates both a curative treatment and / or a prophylactic treatment of a cancer. In the context of cancer, this includes, inter alia, the alleviation of symptoms, the reduction of inflammation, the inhibition of cancer cell growth, and / or the reduction of tumor size. For example, in the case of cancer, a response to treatment includes a reduction in cachexia, increase in survival time, elongation in time to tumor progression, reduction in tumor mass, reduction in tumor burden and / or a prolongation in time to tumor metastasis, time to tumor recurrence, tumor response, complete response, partial response, stable disease, progressive disease, progression free survival, overall survival, each as measured for example by standards set by the National Cancer Institute and the U.S. Food and Drug Administration for the approval of new drugs (Johnson et al., J. Clin. Oncol., 2009; 21(7): 1404-1411).
[0067] The term "normal" refers to the healthy state or the conditions in a healthy subject or tissue, i.e., non- pathological conditions, wherein "healthy" preferably means non-cancerous.
[0068] As used herein, the term “effective amount” or “therapeutic effective amount” refers to a quantity of an active substance (i.e., the tumor specific peptide, combination, multimeric antigen, nucleic acid, vector, cell, antibody, TCR or CAR, as described herein), or a pharmaceutical composition comprising such an active substance, which prevents, removes or reduces the deleterious effects of the cancer. The amount to be administered can be determined by standard procedures well known by those of ordinary skill in the art. The “effective amount” may vary depending on the agent(s), the cancer and its severity, the characteristics of the subject to be treated including age, physical condition, size, gender and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. The amount may also vary according to other components of a treatment protocol (e.g., administration of other medicaments, etc.). These factors are known to those of ordinary skill in the art.
[0069] The term “vaccine” is to be understood as meaning a composition for generating immunity for the prophylaxis and / or treatment of a cancer. Vaccines in the context of the present invention are medicaments which comprise one or more tumor specific peptide(s), antigen(s), combination(s), multimeric antigens(s) nucleic acid(s), vector(s), cell(s), as described herein, and are intended to be used in humans for generating specific defense and protective substance by vaccination. A “vaccine composition” can include a pharmaceutically acceptable excipient, carrier or diluent.
[0070] The term “and / or” as used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example, “A and / or B” is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually.
[0071] The term “a” or “an” can refer to one of or a plurality of the elements it modifies (e.g., “a peptide” can mean one or more peptides) unless it is contextually clear either one of the elements or more than one of the elements is described.
[0072] Tumor specific peptides and combinations thereof
[0073] The present invention provides IncRNA-translated peptides which are tumor specific peptides or fragments thereof.
[0074] In a particular embodiment, said tumor specific peptides are derived from the translated ORF sequences of long noncoding RNAs (IncRNAs), wherein said tumor specific peptides result from expression of DIS3- sensitive IncRNAs, and wherein the expression of said DIS3-sensitive IncRNAs is increased in the cytoplasm of DIS 3 -defective cells. More particularly, the inventors identified several hundred of short ORF in IncRNAs that are translated in DIS3-depleted cells, and they identified among the translated ORF sequences, peptides having strong affinity for MHC class 1 and 2. Then, based on cohort of 211 patients in comparison to 64 samples from bone marrow of healthy donors, the inventors showed a correlation between mutation of DIS3 in MM patients and higher expression of the DIS3-sensitive IncRNAs. Among those higher expressed IncRNAs, the inventors have identified 66 differentially expressed ORFs detected in ribosome -profiling experiment in the in vitro model. These IncRNA derived ORFs can be a source of polypeptides which are predicted to be strongly bound to MHC1 complex. Based on the comparison of expression of those ORFs in the different healthy tissues from GTEx database, 16 were identified to have a high potential to be tumor specific antigens (TSA).
[0075] Preferably, the peptides of the invention strongly bind to a MHC or HLA molecule of Class I and / or II. In another preferred embodiment, the peptides of the invention are not expressed in any healthy, nondiseased tissue such as a non-cancerous tissue.
[0076] The inventors also confirmed the presence of the translated IncRNA ORFs in DIS3 -depleted cells by immunopeptidomic experiments where MHC1 complex was purified from DIS3 -depleted cells and eluted peptides were analyzed using mass spectrometry.
[0077] Additionally, data from immunopeptidomic experiments coming from 10 patients and 5 MM cell lines (Walz et al., 2015) were reanalyzed, using the database of amino acids.
[0078] The analysis of all immunopeptidomic data identified unique peptides coming from IncRNAs sORFs. Further, nucleotide sequence of ORFs that are the source of the abovementioned peptide coming from IP experiment were queried for their expression level in healthy tissues. Based on the 90thpercentile expression criteria of TPM< 1 one of the ORFs from IP experiment was retained as particularly relevant (SEQ ID NO: 17 in Table 1). Additionally, 4 more sORFs that were expressed in MM and 3 of them only in testis were included. From those, one was identified by Ribo-seq (SEQ ID NO: 55 in Table 1), two by analysis of immunopeptidomic of KMM-1 cell line (SEQ ID NO: 56 and 61 in Table 1) and one from Walz et al. data for U266 MM cell line (SEQ ID NO: 57 in Table 1). These are encouraging results and validation of the data by further immunopeptodomic experiments in MM cell lines with DIS 3 mutations and addition of synthetic heavy-labeled peptides from the 17 Ribo-seq identified ORFs would be important point strengthening the data.
[0079] In another particular embodiment, the tumor specific peptides are immunogenic and induce a T-cell response.
[0080] In a first aspect of the present invention, the inventors identified new translated ORF sequences expressed from IncRNA and tumor specific peptides derived from these ORFs, but also new tumor specific peptides identified by immunopeptidomics.
[0081] Accordingly, the present invention relates to a tumor specific peptide, or a fragment thereof, wherein said peptide: (i) is derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55, 56, 61 and 64-81, with the proviso that when said translated ORF sequence is SEQ ID NOs: 17, the tumor specific peptide derived from this ORF sequence is other than that of SEQ 37; or (ii) comprises, essentially consists of, or consists of a sequence selected from the group consisting of SEQ ID NOs: 18-36, 58, 59, 62, 63 and 82-104 (as shown in Table 1 below). Preferably, the peptide is between 8 to 30 amino acids in length.
[0082] In a preferred aspect, said peptide (i) is derived from the translated ORF sequence from long noncoding RNA (IncRNA), said translated ORF sequence being selected from any of SEQ ID NOs: 1-3, 7, 17 and 64- 81 with the proviso that when said translated ORF sequence is SEQ ID NOs: 17, the tumor specific peptide derived from this ORF sequence is other than that of SEQ 37, preferably from any of SEQ ID NOs: 1-3, 7 or 17 with the proviso that when said translated ORF sequence is SEQ ID NOs: 17, the tumor specific peptide derived from this ORF sequence is other than that of SEQ 37; or (ii) comprises, essentially consists of, or consists of a sequence selected from the group consisting of SEQ ID NOs: 82-104, preferably SEQ ID NO: 96-98, 101 and 102. Preferably, the peptide is between 8 to 30 amino acids in length.
[0083] In another aspect of the present invention, the inventors identified translated ORF sequences expressed from IncRNA and tumor specific peptides derived from these ORFs and in addition other tumor specific peptides. These tumor specific peptides can be used as a combination of peptides or as multimeric antigens. Accordingly, the invention relates to a combination comprising at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides, wherein said peptides:
[0084] (i) are derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55-57, 61 and 64-81; and / or
[0085] (ii) comprise, essentially consist of, or consist of a sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104.
[0086] Optionally, said peptides used as a combination:
[0087] (i) are derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-3, 7, 17 and 64-81, preferably any of SEQ ID NOs: 1-3, 7 and 17; and / or
[0088] (ii) comprise, essentially consist of, or consist of a sequence selected from any of SEQ ID NOs: 82- 104, preferably SEQ ID NOs: 96-98, 101 and 102.
[0089] Preferably, the peptides are between 8 to 30 amino acids in length.
[0090] More particularly, the peptides can be about 8 to 25 amino acids in length. Typically, the peptides can bind MHC class I molecules and can be about 8 amino acids to 15 amino acids in length, for instance 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in length. Alternatively, the peptides can bind MHC class II molecules and can be about 13 amino acids to 25 amino acids in length, for instance 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids in length. Preferably, the peptides bind MHC class I molecules.
[0091] The peptide strongly binds to a MHC or HLA molecule of Class I or II. For the purpose of this invention for peptides not identified directly in IP experiment, NetMHCpan-4.1 and NetMHCIIpan-4.0 (Reynisson et al. 2020; Hoof et al. 2009) computational methods were used. This tool includes information about the HLA alleles determined by transcriptomic data for the MM cohort of patients to predict the binding affinity to MHC complex based on the rank score in comparison to natural peptides. Only the top random natural peptides below 0.5% with length of 8-14 amino acid are retained. The methods for assessing this binding are available for the person skilled in the art. For instance, the MHCflurry or NetMHCpan computational methods can be used to predict MHC class I display of a peptide by an HLA allele; and the NetMHCIIpan computational method can be used to predict MHC class II display of a peptide by an HLA allele (Reynisson et al., 2020). Other methods of determining peptide -HLA binding are disclosed in WO 2005 / 042698. ELISPOT assay (Slota et al., 2011) or MIRA assay (Klinger et al., 2015) can also be used to score peptide display (e.g., a peptide immunogenicity that requires peptide binding) by an MHC molecule.
[0092] Optionally, the peptide is derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55, 56, 61 and 64-81, from any of SEQ ID NOs: 1-17 and 64-81, from any of SEQ ID NOs: 1-7, 17 and 64-81, or from any of SEQ ID NOs: 1-3, 7, 17 and 64-81, or from any of SEQ ID NOs: 1-3, 7 and 17, with the proviso that when said translated ORF sequence is SEQ ID NOs: 17, the tumor specific peptide derived from this ORF sequence is other than that of SEQ 37.
[0093] More precisely, the peptide derived from the translated ORF sequence from IncRNA, comprises, essentially consists of, or consists of a sequence of 8 or 9 consecutive amino acids of any ORF translated sequence selected from any of SEQ ID NOs: 1-17, 55, 56, 61 and 64-81, from any of SEQ ID NOs: 1-17 and 64-81, from any of SEQ ID NOs: 1-7, 17 and 64-81, or from any of SEQ ID NOs: 1-3, 7, 17 and 64-81, or from any of SEQ ID NOs: 1-3, 7 and 17, with the proviso that when said translated ORF sequence is SEQ ID NOs: 17, the tumor specific peptide derived from this ORF sequence is other than that of SEQ 37. Optionally, said peptide may further comprise 1 or 2 substitutions with said 8 or 9 consecutive amino acids. The substitutions are in particular introduced for increasing the binding of the peptide to MHC, especially by substitutions carried in the two anchor residues.
[0094] Optionally, the peptide derived from the translated ORF sequence from IncRNA, essentially consists of, or consists of a sequence of 8 or 9 consecutive amino acids of any ORF translated sequence selected from any of SEQ ID NOs: 1-17, 55, 56, 61 and 64-81, from any of SEQ ID NOs: 1-17 and 64-81, from any of SEQ ID NOs: 1-7, 17 and 64-81, or from any of SEQ ID NOs: 1-3, 7 and 17 and 64-81, or from any of SEQ ID NOs: 1-3, 7 and 17, with the proviso that when said translated ORF sequence is SEQ ID NOs: 17, the tumor specific peptide derived from this ORF sequence is other than that of SEQ 37; and wherein: the sequence further comprises 0, 1 or 2 substitutions; and / or, the sequence further comprises the addition of 0, 1, 2, 3, 4 or 5 amino acids at the N and / or C- terminal ends of the peptide; and / or, the sequence further comprises the deletion of 0, 1, 2, 3, 4 or 5 amino acids at the N and / or C- terminal ends of the peptide with the provision that the peptide is at 8 amino acids in length. Optionally, the peptide comprises, essentially consists of, or consists of a sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104, the group consisting of SEQ ID NOs: 18-37, 82-104, the group consisting of SEQ ID NOs: 18-37, 96-98, 101 and 102, the group consisting of SEQ ID NOs: 18-25, 37, 96-98, 101 and 102, the group consisting of SEQ ID NOs: 18-20, 25, 37, 96-98, 101 and 102, or the group consisting of SEQ ID NOs: 96-98, 101 and 102.
[0095] Optionally, the peptide comprises, essentially consists of, or consists of a sequence of 8 or 9 consecutive amino acids of any sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104, the group consisting of SEQ ID NOs: 18-37, 82-104, the group consisting of SEQ ID NOs: 18-37, 96-98, 101 and 102, the group consisting of SEQ ID NOs: 18-25, 37, 96-98, 101 and 102, the group consisting of SEQ ID NOs: 18-20, 25, 37, 96-98, 101 and 102, or the group consisting of SEQ ID NOs: 96- 98, 101 and 102, said peptide may further comprise 1 or 2 substitutions with said 8 or 9 consecutive amino acids. The substitutions are in particular introduced for increasing the binding of the peptide to MHC, especially by substitutions carried in the two anchor residues of the sequence bound by MHC class I molecules, typically located at positions 2 and 8, 9 or 11.
[0096] Optionally, the peptide consists of a sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104, the group consisting of SEQ ID NOs: 18-37, 82-104, the group consisting of SEQ ID NOs: 18-37, 96-98, 101 and 102, the group consisting of SEQ ID NOs: 18-25, 37, 96-98, 101 and 102, the group consisting of SEQ ID NOs: 18-20, 25, 37, 96-98, 101 and 102, or the group consisting of SEQ ID NOs: 96-98, 101 and 102, and wherein: the sequence further comprises 0, 1 or 2 substitutions; and / or, the sequence further comprises the addition of 0, 1, 2, 3, 4 or 5 amino acids at the N and / or C- terminal ends of the peptide; and / or, the sequence further comprises the deletion of 0, 1, 2, 3, 4 or 5 amino acids at the N and / or C- terminal ends of the peptide with the provision that the peptide is at 8 amino acids in length.
[0097] Optionally, the peptide consists of a sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104, the group consisting of SEQ ID NOs: 18-37, 82-104, the group consisting of SEQ ID NOs: 18-37, 96-98, 101 and 102, the group consisting of SEQ ID NOs: 18-25, 37, 96-98, 101 and 102, the group consisting of SEQ ID NOs: 18-20, 25, 37, 96-98, 101 and 102, or the group consisting of SEQ ID NOs: 96-98, 101 and 102.
[0098] Optionally, the peptide bond(s) of the peptide can be modified to make them resistant to proteolysis. For example, at least one peptide bond (-CO-NH-) may be replaced with a divalent bond chosen from (-CH2- NH-), (-NH-CO-), (-CH2-0-), (-CH2-S-), (-CH2-CH2-), (-C0-CH2-), (-CH0H-CH2-), (-N=N-) and (- CH=CH-). Optionally, all the peptide bonds may be replaced.
[0099] Optionally, the peptide molecule may comprise either a carboxylic (-COO-) or amidated (-C0NH2) C- terminal end. The C-terminal end may also be esterified. The peptide may also be optionally modified at its N-terminal end, for example with an acetyl radical. In a particular embodiment, the peptide may be PEGylated (polyethylene glycol), in part at its N-terminal end. For example, the peptide may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more PEG groups.
[0100] Optionally, the invention further relates to a combination comprising 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides as defined herein.
[0101] The invention further relates to a recombinant, chimeric or multimeric antigens comprising at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides as defined above. Optionally, the invention further relates to a recombinant, chimeric or multimeric antigen comprising 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides as defined above.
[0102] Optionally, the invention further relates to a combination of recombinant, chimeric or multimeric antigens as described herein.
[0103] Translated ORF sequences and tumor specific peptides sequences, identified by the inventors, are listed in the below Table 1.
[0104] Preferred ORFs are based on % of discrimination healthy versus MM and in second line having potential to produce peptides strongly bound by most common HLA allele types, for example HLA*A02:01; and preferred peptides are based on the rank score of binding predicted by NetMHCpan-4.1.
[0105] Table 1: List of the translated ORFs sequences from IncRNAs and tumor specific peptides sequences.
[0106]
[0107] ND: Not Determined
[0108] Each of the above peptides, or fragments or variants thereof, may represent an antigen of interest in the context of a peptide based vaccine or in the context of a TCR engineered T cells based therapy or CAR-T cells based therapy according to the invention. The peptides of particular interest of Table 1 are listed in Table 5 below, and are further described in Example 6 of the experimental part.
[0109] Optionally, the peptide can be modified. For instance, the modification can be a conjugation to a molecule. The molecule can comprise or be an antibody, a peptide, a protein, a ligand, a lipid, a carbohydrate, an adjuvant or a detection entity. 1
[0110] The peptide can be conjugated to the molecule either directly or indirectly using a linker or spacer either at the N-terminal end or at the C-terminal end of the peptide. The linker or spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The linkers or spacers are typically selected from, e.g., Ala, Gly or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present linker or spacer need not be comprised of the same residues and may be a hetero- or homo-oligomer. When present, the linker or spacer usually comprises at least one or two residues, more usually three to six residues or more. In case of a multimeric antigen according to the invention, multiple peptides as defined herein can also be linked together, optionally by a linker or spacer.
[0111] The peptide can also be modified to provide desired properties, e.g., improved serum half-life, enhanced immunogenicity or greater chemical stability.
[0112] Half-life of the peptide may be improved, for instance, by PEGylation, glycosylation, polysialylation, Fc fusion, albumin fusion, nanoparticle attachment, nanoparticulate encapsulation, cholesterol fusion, etc.
[0113] In another aspect, the immunogenic activity of the peptide can be enhanced by linkage to another peptide sequence which contains at least one epitope that is capable, for example, of inducing a CD8+ cytotoxic T cells response (CTL response) or a CD4+ T helper cells response. In this regard, the present invention relates to a conjugate comprising a tumor specific peptide as defined herein, which is coupled, via a linker or without any linker, to a peptide inducing a CTL response or a T helper cell response.
[0114] Optionally, the present invention relates to a molecular complex comprising a tumor specific peptide as defined herein and a MHC polypeptide.
[0115] In another embodiment, the peptide can be modified by a conjugation to a carrier molecule to elicit an antibody response. A carrier molecule may be any molecule or protein known in the art such as KLH (Keyhole limpet hemocyanin), ovalbumin, bovine serum albumin (BSA), a viral or bacterial anatoxin such as toxoid, tetanus toxin, diphtheria toxoid, cholera toxin B, mutants thereof such as diphtheria toxin CRM 197, an outer membrane vesicle protein, a polylysine molecule, or a virus like particle (VLP). Coupling of the peptide to a carrier may be performed by covalent chemistry using linking chemical groups or reactions, such as for instance glutaraldehyde, biotin, etc.
[0116] The tumor specific peptides as defined herein are also useful as diagnostic agents to detect cancer. In this regard, the tumor specific peptide or a fragment thereof may be in the form of a derivative in which another constituent such as a detection entity is attached thereto e.g. a radiolabel, biotin, fluorescein. A targeting agent may also be attached to the tumor specific peptide or a fragment thereof that allows for specific targeting to a specific organ, tumor or cell types. Such targeting agents may be hormones, cytokines, cellular receptors and the like. The tumor specific peptide or a fragment thereof may be prepared in the form of a kit, alone or in combination with other reagents.
[0117] The peptides of the invention may be produced by any technique known in the art, including the expression of proteins, polypeptides or peptides through standard molecular biological techniques, the isolation of proteins or peptides from natural sources, or the chemical synthesis of proteins or peptides.
[0118] Nucleic acids, vectors and host cells
[0119] The invention also relates to nucleic acids encoding one or several tumor specific peptides as defined herein.
[0120] The nucleic acids according to the invention may be isolated or purified nucleic acids. The nucleic acid can be DNA (e.g. cDNA), RNA, or a mixture thereof. In a particular embodiment, the invention relates to a combination comprising a set of nucleic acids coding for at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 tumor specific peptides as described herein. Optionally, the invention further relates to a set of nucleic acids coding for 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides as described herein.
[0121] The invention further relates to a nucleic acid or a set of nucleic acids coding for a recombinant, chimeric or multimeric antigen comprising at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 tumor specific peptides as described herein. Optionally, the invention further relates to a nucleic acid or a set of nucleic acids coding for a recombinant, chimeric or multimeric antigen comprising 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides as described herein.
[0122] The nucleic acids or sets of nucleic acids according to the invention can be part of any expression construct as described herein, e.g., cassette, plasmid, cosmid, phage, phagemid, artificial chromosome or vector such as viral or non-viral vector. Viral vectors known for therapeutic purposes are adenoviruses, adeno- associated viruses (AAVs), lentiviruses, retroviruses, canarypox, etc. However, non-viral vectors can also be used such as for example transposon-based vector systems. Nucleic acids can also be delivered through other carriers such as but not limited to nanoparticles, cationic lipids, liposomes etc.
[0123] In a particular embodiment, the present invention relates to a recombinant vector or expression construct comprising a nucleic acid or a set of nucleic acids as described herein. In particular, the vector or expression construct may comprise a nucleic acid or a set of nucleic acids of the invention operably linked to a regulatory region, i.e. a region comprising one or more control sequences. Optionally, the vector or expression construct may comprise several nucleic acids of the invention operably linked to several regulatory regions. The term “control sequences” means nucleic acid sequences necessary for expression of a coding region. Control sequences may be endogenous or heterologous. Well-known control sequences and currently used by the person skilled in the art will be preferred. Such control sequences include, but are not limited to, promoter, enhancer, signal peptide sequence and transcription terminator. The term “operably linked” means a configuration in which a control sequence is placed at an appropriate position relative to a coding sequence, in such a way that the control sequence directs expression of the coding region.
[0124] The present invention further relates to the use of a nucleic acid, a set of nucleic acids or vector according to the invention to transform, transfect or transduce a host cell or to produce a composition, such as a pharmaceutical composition, to transform, transfect or transduce a host cell.
[0125] The present invention also provides a recombinant host cell comprising one or several nucleic acids of the invention and / or one or several vectors of the invention. The term “host cell” also encompasses any progeny of a parent host cell that is not identical to the parent host cell due to mutations that occur during replication. Suitable host cells may be prokaryotic (e.g., a bacterium) or eukaryotic (e.g., yeast, plant, insect or mammalian cell). Specific illustrative examples of such cells include E. coli strains, CHO cells, Saccharomyces strains, plant cells, sf9 insect cells etc. The present invention also concerns a method for producing a peptide of the invention, comprising culturing a host cell comprising a nucleic acid of the invention or a vector of the invention, as provided above, under conditions suitable for expression of the peptide, and optionally recovering the peptide from the host cell or from the host cell culture medium. Optionally, the recovered peptide may be further purified or isolated. Suitable media, culture conditions and production method are well-known by the skilled person and can be easily chosen according to the host cell and the peptide to be produced.
[0126] The peptides of the invention may also be produced synthetically according to any method known in the art.
[0127] Antibodies. TCRs, CARs and immune cells specifically binding tumor specific peptides
[0128] This invention further provides an antibody or antigen binding fragment thereof that specifically binds a tumor specific peptide or a combination thereof as defined herein. Such antibodies can be elicited by immunization of the tumor specific peptide of the present invention. For instance, the tumor specific peptide may be conjugated to a carrier protein in order to elicit an antibody response. Carrier proteins such as KLH, tetanus toxoid and the like and methods of conjugation are known in the art. The antibody has specificity for and reacts or binds with the peptide of the present invention.
[0129] As used herein, the term “antibody” or “immunoglobulin” refers to monoclonal antibodies, polyclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, camel antibodies (e.g., as VHH, sdAb), chimeric antibodies, antigen binding fragments such as single-chain variable fragment (scFv), single chain antibodies, single domain antibodies, antigen-binding fragments (Fab), F(ab') fragments, disulfide-linked variable fragment (sdFv), intrabodies, nanobodies, and epitope -binding fragments of any of the above. In particular, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules that contain an antigen binding site. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass. Unless specifically noted otherwise, the term “antibody” includes intact immunoglobulins and “antibody fragments” or “antigen binding fragments” that specifically bind to one or more proteins or peptides of interest to the substantial exclusion of binding to other molecules. The term “antibody” also includes genetically engineered forms such as chimeric antibodies (for example, humanized murine antibodies), heteroconjugate antibodies (such as bispecific antibodies). Polyclonal or monoclonal antibodies may be produced by methods known in the art.
[0130] In a particular aspect, the present invention further relates to a nucleic acid coding for such an antibody or antigen binding fragment thereof; or to a vector comprising the nucleic acid coding for such an antibody or antigen binding fragment thereof.
[0131] The antibodies or antigen binding fragments of the present invention may be used in immunotherapy. In a particular embodiment, the antibody or antigen binding fragment thereof is administered to a subject in an amount sufficient to prevent, lessen or attenuate the severity, extent or duration of the cancer. For instance, as the antibodies are specific of tumors, they can be used for inducing the killing of tumor cells, for instance by inducing antibody-dependent cellular cytotoxicity (ADCC). Alternatively, the antibodies can be coupled to toxins, radionuclides or drugs in order to mediate the specific killing of tumor cells. Accordingly, they can be used to prepare an antibody-drug conjugate (ADC). More generally, they can be used for specifically delivering a drug to the tumor due to its capacity of targeting tumor cells.
[0132] The antibodies reactive with the tumor specific peptides as defined herein, may also be used in diagnostic and detection assays for detecting cancer. The antibodies may be provided in the form of a kit alone, or along with other reagents commonly used in diagnostic and detection assays. For example, the antibodies may be used to detect tumor peptides in a biopsy sample from a subject having a cancer or likely to have a cancer. Assessment of the tumor antigen in a diseased tissue can be used to diagnose the cancer, prognose the progression of the cancer or diagnose the efficacy of a treatment of the cancer. The immunoassay may be a radioimmunoassay, Western blot assay, immunofluorescent assay, enzyme immunoassay, chemiluminescent assay, immunohistochemical assay and the like and may be performed in vitro, in vivo or in situ. The biological sample appropriate for such detection assays may be any sample from a subject such as a tissue biopsy, cells extract, whole blood, plasma, serum, bone marrow, cerebrospinal fluid, urine and the like. In a particular embodiment, the biological sample is a sample containing tumor cells.
[0133] To promote the infiltration and recognition of tumor cells by lymphocytes T, another strategy consists in using antibodies which are capable of recognizing more than one antigenic target simultaneously and more particularly two antigenic targets simultaneously (i.e., bispecific antibodies). Thus, in another particular aspect, the antibody of the invention is a bi-specific antibody, typically derived from a TCR-like antibody that specifically binds a tumor peptide as described herein, optionally in combination with a MHC or an HLA molecule and which further targets at least one immune cell antigen. Typically, the immune cell is a T cell, a NK cell or a dendritic cell, and the targeted immune cell antigen may be for instance CD3, CD16, CD30 or a TCR, etc.
[0134] As mentioned above, the tumor specific peptides of the invention, or fragments thereof, may represent an antigen of interest in the context of a TCR engineered T cells based therapy or CAR-T cells based therapy. In this regard, the invention relates to a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds a peptide of the invention, for use in cell therapy of any cancer as described herein.
[0135] In a particular embodiment, the invention thus relates to “T cell receptors (TCRs)” that bind one or more tumor specific peptides of the invention. T cell receptors (TCR) are cell surface receptors that participate in the activation of T cells in response to the presentation of antigen. The TCR is generally made from two chains, alfa and beta, which assemble to form a heterodimer and associates with the CD3 -transducing subunits to form the T cell receptor complex present on the cell surface. Each alfa and beta chain of the TCR consists of an immunoglobulin-like N-terminal variable (V) and constant (C) region, a hydrophobic transmembrane domain, and a short cytoplasmic region. As for immunoglobulin molecules, the variable region of the alfa and beta chains are generated by V(D)J recombination, creating a large diversity of antigen specificities within the population of T cells. However, in contrast to immunoglobulins that recognize intact antigen, T cells are activated by processed peptide fragments in association with an MHC molecule, introducing an extra dimension to antigen recognition by T cells, known as MHC restriction.
[0136] The present invention also relates to a method of producing a TCR, or an antigen-binding fragment thereof, comprising a step of selecting TCRs that bind to a tumor specific peptide as defined herein, optionally in association with an MHC or HLA molecule, optionally with a Kd binding affinity of from about 10-6 M to about 10-1 IM, for example 10-6 M or less, 10-7 M or less, 10-8 M or less, 10-9 M or less, 10-10 M or less, or 10-11 M or less. Nucleic acid encoding the TCR can be obtained from a variety of sources, such as by polymerase chain reaction (PCR) amplification of naturally occurring TCR DNA sequences, followed by expression of antibody variable regions, followed by the selecting step as described above. In other embodiments, the TCR is obtained from T-cells isolated from a patient, or from cultured T-cell hybridomas or by any genetic engineering technique known in the art.
[0137] The invention also relates to a method of producing a TCR, wherein the tumor specific antigen as defined herein is loaded onto class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or artificial antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen- presenting cell, or the antigen is loaded onto class I or II MHC tetramers by tetramerizing the antigen / class I or II MHC complex monomers.
[0138] In another embodiment, TCRs of the invention may further comprise a detectable label such as a radionuclide, a fluorophore or biotin. TCRs of the present invention may also be conjugated to a therapeutically active agent, such as a radionuclide, a chemotherapeutic agent or a toxin.
[0139] In another particular embodiment, the invention relates to “chimeric antigen receptors (CARs)” that bind one or more tumor specific peptides of the invention.
[0140] In the context of the present invention, the term “Chimeric antigen receptor” or “CAR” refers to an engineered receptor which grafts an antigen binding specificity onto immune cells (e.g. T cells or NK cells), thus combining the antigen binding properties of the antigen binding domain with the immunogenic activity of the immune cell, such as the lytic capacity and self-renewal of T cells. Particularly, a CAR refers to a fused protein comprising an extracellular domain able to bind one or more peptides according to the invention, a transmembrane domain, optionally a hinge domain and at least one intracellular domain. The terms “extracellular domain able to bind an antigen” and “antigen binding domain” are used interchangeably herein and mean any peptide, oligopeptide or polypeptide that can bind to a targeted antigen. In a particular aspect, the term "antigen binding domain" as used herein refers to the region of the CAR which targets and binds to specific antigens according to the invention, i.e., tumor specific antigens or combinations thereof as described herein. When a CAR is expressed in a host cell, this domain forms the extracellular domain (ectodomain) of the receptor. The antigen binding domain of a CAR typically derives from an antibody and may consist of an antigen-binding domain of a single-chain antibody (scFv) or antigen -binding fragments (Fab). The term “intracellular domain” and “intracellular signaling domain” are used interchangeably herein and mean any peptide, oligopeptide or polypeptide known to function as a domain that transmits a signal that causes activation or inhibition of a biological process in a cell. The intracellular signaling domain may generate a signal that promotes an immune effector function of the cell transduced with a nucleic acid sequence comprising a CAR, e.g. cytolytic activity and helper activity, including the secretion of cytokines. The term “transmembrane domain” means any peptide, oligopeptide or polypeptide known to span the cell membrane and that can function to link the extracellular and signaling domains. This may be a single alpha helix, a transmembrane beta barrel, a beta-helix of gramicidin A, or any other structure. Typically, the transmembrane domain denotes a single transmembrane alpha helix of a transmembrane protein, also known as an integral protein. A chimeric antigen receptor may optionally comprise a “hinge domain” which serves as a linker between the extracellular and transmembrane domains. As used herein the term “hinge”, “spacer” or “linker” refers to an amino acid sequence of variable length typically encoded between two or more domains of a polypeptide construct to confer for example flexibility, improved spatial organization and / or proximity.
[0141] CARs according to the invention are synthetic tumor targeting receptors that can be introduced into human immune cells such as T cells or NK cells to redirect antigen specificity and enhance functions of effector immune cells.
[0142] CARs can thus be used to direct immune cells such T-cells or NK cells against a tumor specific peptide as defined herein with a suitable antigen-binding domain selected in its extracellular portion.
[0143] For example, the CAR may include in its extracellular portion, one or more antigen binding molecules, such as one or more antigen-binding fragments, domains (such as scFv), or portions of an antibody and / or antibody molecules directed against the tumor specific peptides as defined herein. Typically, the antigenbinding domain of the CAR is based on a scFv derived from an antibody. According to particular embodiments, the present invention thus relates to an antibody, a T cell receptor (TCR) or a chimeric antigen receptor (CAR) that is directed against one or more tumor specific peptides of the invention and that specifically binds one or more tumor specific peptides of the invention.
[0144] In other embodiments, the invention also relates to an antibody, a TCR, or a CAR, or a variant or a derivative thereof, which is directed against one or more tumor specific peptides as defined herein, optionally in association with an MHC or HLA molecule.
[0145] In other embodiments, the present invention also relates to a nucleic acid coding for such an antibody, TCR or CAR that specifically binds a peptide or combination of the invention; or to a vector comprising the nucleic acid coding for such an antibody, TCR or CAR; or to uses thereof in cell therapy of any cancer as described herein. In a further embodiment, the invention also relates to a recombinant immune cell that (i) specifically binds to one or more peptides as defined herein; or (ii) comprises a TCR or CAR that specifically binds a peptide as defined herein; a nucleic acid coding for such TCR or CAR; or a vector comprising the nucleic acid coding for such TCR or CAR. In a particular embodiment, the invention relates to an immune cell, especially a T cell, that comprises a nucleic acid coding for a TCR or CAR as described herein or a vector comprising said nucleic acid, for use in cell therapy of any cancer as described herein.
[0146] As used herein, the term “immune cell” includes cells that are of hematopoietic origin and that play a role in the immune response. Immune cells include lymphocytes, such as B cells and T cells, natural killer cells, myeloid cells, such as monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes. The immune cell is preferably selected from a group consisting of a T cell, CD4+ T cell, CD8+ T cell, B cell, NK cell, NKT cell, monocyte and dendritic cell. Typically, the immune cell is for use in cell therapy of cancer.
[0147] Methods by which immune cells can be genetically modified to express a recombinant antigen receptor are well known in the art. A nucleic acid molecule encoding the antigen receptor may be introduced into the cell in the form of e.g. a vector, or any other suitable nucleic acid construct. Vectors, and their required components, are well known in the art. Nucleic acid molecules encoding antigen receptors can be generated using any method known in the art, e.g. molecular cloning using PCR. Antigen receptor sequences can be modified using commonly-used methods, such as site-directed mutagenesis.
[0148] In another particular embodiment, the invention relates to the use of a TCR or CAR, nucleic acid, vector or immune cell, for the manufacture of a medicament for treating a cancer in a subject in need thereof.
[0149] The invention is particularly suitable to treat cancer or prevent cancer relapse. Preferably, the cancer is a cancer associated with an alteration or loss of the DIS3 gene selected from multiple myeloma, acute myeloid leukaemia, chronic myelomonocytic leukaemia, chronic lymphocytic leukaemia, small lymphocytic lymphoma, plasma cell leukemia, mantle cell lymphoma, B-cell lymphoblastic leukemia / lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, glioblastoma, conventional glioblastoma multiforme, glioma, high-grade glioma, anaplastic astrocytoma, ovarian cancer, high grade ovarian serous adenocarcinoma, uterine cancer, uterine corpus leiomyosarcoma, breast cancer, invasive breast carcinoma, breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast invasive lobular carcinoma, prostate adenocarcinoma, skin cancer, melanoma, superficial spreading melanoma, cutaneous melanoma, acral lentiginous melanoma, Merkel cell carcinoma, lung cancer such as non-small cell lung carcinoma, lung adenocarcinoma, small cell lung carcinoma, leiomyosarcoma, neuroendocrine tumor, neuroendocrine carcinoma, hepatocellular carcinoma, bladder urothelial carcinoma, gastrointestinal stromal tumor and small intestinal neuroendocrine tumor; preferably multiple myeloma, and in particular multiple myeloma characterized by DIS3 gene deregulation such as DIS3 gene mutation or misexpression. In another particular embodiment, the invention is suitable to treat any disease associated with an alteration or loss of the DIS 3 gene.
[0150] Pharmaceutical compositions, regimen and administration
[0151] The invention also relates to a pharmaceutical composition, in particular a therapeutic composition, characterized in that it comprises the above tumor specific peptide, a combination thereof, a multimeric antigen as defined above, a nucleic acid or set of nucleic acids as defined above, a recombinant vector or cell as defined above, an antibody specifically binding one of the above tumor specific peptides, a TCR, CAR or immune cell as described herein.
[0152] In a particular aspect, the pharmaceutical composition further comprises one or more pharmaceutically acceptable carrier(s) or excipient(s).
[0153] The invention further relates to a pharmaceutical composition as disclosed herein for use in the treatment of a cancer or for the prevention of cancer relapse. It also relates to the use of a pharmaceutical composition as disclosed herein for the manufacture of a medicament for the treatment of a cancer or for the prevention of cancer relapse. In addition, it relates to a method for the treatment of a cancer or for the prevention of cancer relapse in a subject in need thereof, comprising administering a therapeutic amount of a pharmaceutical composition as disclosed herein to said subject.
[0154] The pharmaceutical composition of the invention is particularly suitable for preventing or treating any cancer associated with an alteration of the DIS3 gene, or for preventing a relapse of such cancer. Preferably, the cancer that can be treated according to the invention, is multiple myeloma, acute myeloid leukaemia, chronic myelomonocytic leukaemia, chronic lymphocytic leukaemia, plasma cell leukemia, glioblastoma, ovarian cancer, breast cancer, skin cancer, melanoma, superficial spreading melanoma or prostate adenocarcinoma.
[0155] In a particular embodiment, the invention is particularly suitable for treating multiple myeloma at any stage of progression or for preventing multiple myeloma relapse, preferably multiple myeloma characterized by DIS3 gene deregulation such as DIS3 mutation or misexpression.
[0156] The peptide of the invention can be used in the form of any pharmaceutically acceptable salt. The expression “pharmaceutically acceptable salts” refers to, for example and in a non-restrictive way, pharmaceutically acceptable base or acid addition salts, hydrates, esters, solvates, precursors, metabolites or stereoisomers.
[0157] The expression “pharmaceutically acceptable salts” refers to nontoxic salts, which can be generally prepared by reacting a free base with a suitable organic or inorganic acid. These salts preserve the biological effectiveness and the properties of free bases. Representative examples of such salts include water-soluble and water-insoluble salts such as acetates, N-methylglucamine ammonium, amsonates (4,4- diaminostilbene-2,2’-disulphonates), benzenesulphonates, benzonates, bicarbonates, bisulphates, bitartrates, borates, hydrobromides, bromides, buryrates, camsylates, carbonates, hydrochlorates, chlorides, citrates, clavulanates, dichlorhydrates, diphosphates, edetates, calcium edetates, edisylates, estolates, esylates, fumarates, gluceptates, gluconates, glutamates, glycolylarsanylates, hexafluorophosphates, hexylresorcinates, hydrabamines, hydroxynaphthoates, iodides, isothionates, lactates, lactobionates, laurates, malates, maleates, mandelates, mesylates, methylbromides, methylnitrates, methylsulphates, mucates, napsylates, nitrates, 3-hydroxy-2-naphthoates, oleates, oxalates, palmitates, pamoates (1,1- methylene-bis-2-hydroxy-3-naphtoates, or emboates), pantothenates, phosphates, picrates, polygalacturonates, propionates, p-toluenesulphonates, salicylates, stearates, subacetates, succinates, sulphates, sulphosalicylates, suramates, tannates, tartrates, teoclates, tosylates, triethiodides, trifluoroacetates and valerianates.
[0158] As mentioned above, the compositions of the invention advantageously comprise one or more pharmaceutically acceptable carriers, excipients or diluents that can be selected from the carriers or excipients known in the art and classically used according to each mode of administration. According to the mode of administration envisaged, the composition can be in solid, semi-solid or liquid form. For solid compositions such as tablets, pills, powders, or granules that are free or are included in gelatin capsules, the active substance can be combined with: a) diluents, for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine; b) lubricants, for example silica, talc, stearic acid, its magnesium or calcium salt and / or polyethylene glycol; c) binders, for example magnesium and aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethyl cellulose and / or polyvinylpyrrolidone; d) disintegrants, for example starch, agar, alginic acid or its sodium salt, or effervescent mixtures; and / or d) absorbents, dyes, flavoring agents and sweeteners. The excipients can be, for example, mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate and analogues of pharmaceutical quality. For semi-solid compositions such as suppositories, the excipient can, for example, be an emulsion or oily suspension, or polyalkylene glycol-based, such as polypropylene glycol. Liquid compositions, in particular injectables or those included in a soft capsule, can be prepared, for example, by dissolution, dispersion, etc., of the active substance in a pharmaceutically pure solvent such as, for example, water, physiological saline solution, aqueous dextrose, glycerol, ethanol, oil and analogues thereof.
[0159] The compositions of the invention can be administered by any suitable route and, in a non-restrictive way, by parenteral route, such as, for example, in the form of preparations that can be injected by subcutaneous, intravenous or intramuscular route; by intra-tumoral administration; by oral route (or per os), such as, for example, in the form of coated or uncoated tablets, gelatin capsules, powders, pellets, suspensions or oral solutions (one such form for oral administration can be either with immediate release or with extended or delayed release); by rectal route such as, for example, in the form of suppositories; by topical route, in particular by transdermal route, such as, for example, in the form of patches, pomades or gels; by intranasal route such as, for example, in aerosol and spray form; by perlingual route; or by intraocular route.
[0160] Preferably, the pharmaceutical composition as described herein is administered by intra-tumoral, intravenous or subcutaneous route.
[0161] The pharmaceutical compositions of the invention typically comprise an effective dose of an active substance according to the invention. A “therapeutically effective dose” as described herein refers to the dose that gives a therapeutic effect for a given condition and administration schedule. It is typically the average dose of an active substance to administer to appreciably improve some of the symptoms associated with a disease or a pathological state. For example, in treating a cancer, e.g., blood cancer (such as multiple myeloma), glioblastoma, ovarian cancer, breast cancer, uterine cancer, prostate adenocarcinoma, skin cancer, etc., the dose of an active substance that decreases, prevents, delays, eliminates or stops one of the causes or symptoms of the cancer would be therapeutically effective. A “therapeutically effective dose” of an active substance does not necessarily cure the cancer but will provide a treatment for the cancer so that its appearance is delayed, impeded or prevented, or cancer relapse is prevented, or cancer symptoms are attenuated, or its term is modified or, for example, is less severe, or the recovery of the patient is accelerated.
[0162] The “therapeutically effective dose” of a peptide of the invention is for example of about 1 mg to about 500 mg per subject who will be administered with said peptide.
[0163] It is understood that the “therapeutically effective dose” for a person in particular will depend on various factors, including the activity / effectiveness of the active substance, its time of administration, its route of administration, its toxicity, its rate of elimination and its metabolism, drug combinations / interactions and the severity of the cancer treated on a preventive or curative basis, as well as the age, weight, overall health, sex and / or diet of the subject.
[0164] In particular aspects, a pharmaceutical composition according to the invention may comprise: (i) a peptide of the invention; and / or (ii) a nucleic acid coding for a peptide of the invention; (iii) a recombinant vector comprising a nucleic acid coding for a peptide of the invention, wherein the nucleic acid is optionally linked to a regulatory region; (iv) a cell comprising a recombinant vector of (iii); (v) a combination comprising at least two peptides of the invention or a set of nucleic acids coding for said at least two peptides; (vi) a multimeric antigen comprising at least two peptides of the invention or a nucleic acid coding for said at least two peptides; (vii) an antibody or an antigen-binding fragment thereof, a TCR or a CAR that specifically binds a peptide of the invention; (viii) a nucleic acid coding for an antibody, TCR or CAR that specifically binds a peptide of the invention; (ix) a vector comprising the nucleic acid coding for an antibody, TCR or CAR that specifically binds a peptide of the invention; (x) a recombinant or isolated immune cell that specifically binds to one or more peptides of the invention; (xi) a recombinant or isolated immune cell that comprises a TCR or CAR that specifically binds to a peptide of the invention; (xii) a recombinant or isolated immune cell that comprises a nucleic acid coding for a TCR or CAR that specifically binds to a peptide of the invention; (xiii) a recombinant or isolated immune cell that comprises a vector comprising a nucleic acid coding for a TCR or CAR that specifically binds to a peptide of the invention; or any combination of (i) to (xiii).
[0165] In other particular aspects, the pharmaceutical compositions of the invention are vaccine compositions, immunogenic compositions, antibody compositions, TCR compositions or CAR T-cell compositions, useful for cancer immunotherapy, as described below.
[0166] Optionally, the pharmaceutical composition according to the present invention can further comprise an additional therapeutic agent or can be used in combination with the additional therapeutic agent and / or radiotherapy. The additional therapeutic agent is an anticancer treatment. The anticancer treatment can be surgery, radiotherapy, chemotherapy, immunotherapy or hormone therapy. As used herein, the term “chemotherapy” refers to a cancer therapeutic treatment using chemical or biochemical substances, in particular using one or several antineoplastic agents. The term “immunotherapy” refers to a cancer therapeutic treatment including with therapeutic antibodies. In particular, antibodies are directed against specific antigens such as the unusual antigens that are presented on the surfaces of tumors. As illustrating example, one can cite Trastuzumab or Herceptin antibody that is directed against HER2 and approved by FDA for treating breast cancer. Preferably, therapeutic antibodies functions to deplete tumor cells in a patient. In particular, therapeutic antibodies specifically bind to antigens present on the surface of the tumor cells, e.g. tumor specific antigens present predominantly or exclusively on tumor cells. Alternatively, therapeutic antibodies may also prevent tumor growth by blocking specific cell receptors. The term “hormone therapy” refers to a cancer treatment having for purpose to block, add or remove hormones. For instance, in breast cancer, the female hormones estrogen and progesterone can promote the growth of some breast cancer cells. So, in these patients, hormone therapy is given to block estrogen and a non-exhaustive list commonly used drugs includes: Tamoxifen, Fareston, Arimidex, Aromasin, Femara, Zoladex / Lupron, Megace, and Halotestin.
[0167] In an aspect, the additional therapeutic agent can be selected in the non-exhaustive list comprising alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, antivirals, aurora kinase inhibitors, apoptosis promoters (for example, Bcl-2 family inhibitors), activators of death receptor pathway, antibody drug conjugates, biologic response modifiers, Bruton's tyrosine kinase (BTK) inhibitors, cyclin-dependent kinase inhibitors, cell cycle inhibitors, growth factor inhibitors, heat shock protein inhibitors, histone deacetylase (HD AC) inhibitors, hormonal therapies, inhibitors of inhibitors of apoptosis proteins (IAPS), intercalating antibiotics, kinase inhibitors, kinesin inhibitors, microRNAs, non-steroidal anti-inflammatory drugs (NSAIDs), platinum chemotherapeutics, proteasome inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine kinase inhibitors, retinoids / deltoids, alkaloids, small inhibitory ribonucleic acids (siRNAs), topoisomerase inhibitors, ubiquitin ligase inhibitors, peptide, DNA or RNA vaccine, cell therapy and the like, as well as combinations of one or more of these agents.
[0168] Optionally, said additional therapeutic agent is a checkpoint inhibitor. The checkpoint inhibitor can be an inhibitor of an immune checkpoint selected from the group consisting of cytotoxic T lymphocyte associated protein (CTLA-4), programmed cell death protein 1 (PD-1), programmed cell death ligand (PD-L1), T cell immunoreceptor with Ig and ITIM domains (TIGIT), Lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), B- and T-lymphocyte attenuator (BLTA), IDO1 inhibitor, or any combination thereof, preferably selected from the group consisting of an antibody directed against PD-1, PD-L1 and CTLA-4 or any combination thereof, more preferably an antibody directed against PD-1 or PD-L1 and the combination thereof.
[0169] Optionally, the additional therapeutic agent is selected among the therapeutic agent used for the treatment of multiple myeloma, for instance thalidomide, bortezomid, lenalidomide, pomalidomide, carfilzomib, daratumumab, ixazomib, isatuximab, panobinostat, elotuzumab, selinexor, teclistamab, corticosteroids, chemotherapy such as cyclophosphamide, etoposide, doxorubicin, liposomal doxorubicin, melphalan, bendamustine, or combination thereof.
[0170] Cancer vaccines
[0171] In a particular aspect, the invention provides a vaccine or immunogenic composition useful in inducing tumor specific immunity against cancer. The vaccine or immunogenic composition of the invention is capable of inducing a specific T-cell immune response.
[0172] Accordingly, the invention relates to a vaccine or immunogenic composition according to the present invention for use in the treatment of a cancer or in the prevention of cancer relapse; to the use of a vaccine or immunogenic composition according to the present invention for the manufacture of a medicament for the treatment of a cancer or for the prevention of cancer relapse; and to a method for the treatment of a cancer or for the prevention of cancer relapse in a subject in need thereof comprising administering to said subject a therapeutic amount of a vaccine or immunogenic composition according to the present invention. The vaccine or immunogenic compositions comprises a tumor specific peptide, a combination of peptides or a multimer antigen as disclosed herein, any nucleic acid or set of nucleic acids encoding them or vector as disclosed herein, and / or cell according to the invention.
[0173] The vaccine compositions according to the invention are suitable for prophylactic or therapeutic treatment of a cancer, preferably for treating any cancer associated with an alteration of the DIS3 gene, or for preventing a relapse of such cancer. In a preferred embodiment, the vaccine of the invention is for preventing or treating multiple myeloma, acute myeloid leukaemia, chronic myelomonocytic leukaemia, chronic lymphocytic leukaemia, small lymphocytic lymphoma, plasma cell leukemia, mantle cell lymphoma, B-cell lymphoblastic leukemia / lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, glioblastoma, conventional glioblastoma multiforme, glioma, high-grade glioma, anaplastic astrocytoma, ovarian cancer, high grade ovarian serous adenocarcinoma, uterine cancer, uterine corpus leiomyosarcoma, breast cancer, invasive breast carcinoma, breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast invasive lobular carcinoma), prostate adenocarcinoma, skin cancer, melanoma, superficial spreading melanoma, cutaneous melanoma, acral lentiginous melanoma, Merkel cell carcinoma, lung cancer, non-small cell lung carcinoma, lung adenocarcinoma, small cell lung carcinoma, leiomyosarcoma, neuroendocrine tumor, neuroendocrine carcinoma, hepatocellular carcinoma, bladder urothelial carcinoma, gastrointestinal stromal tumor and small intestinal neuroendocrine tumor. Such vaccine according to the invention is particularly suitable for treating multiple myeloma at any stage of progression or for preventing multiple myeloma relapse, preferably multiple myeloma characterized by DIS3 gene deregulation such as DIS3 mutation or misexpression. The vaccine may be a peptide vaccine, vectorized vaccine, a DNA vaccine or a plasmid-mediated vaccine, etc. The vaccine may also contain a peptide vaccine and a DNA vaccine.
[0174] In a preferred embodiment, the vaccine according to the invention is a peptide-based vaccine, and the antigen comprises or consists of a peptide as defined herein, or a combination or multimer antigen comprising at least 2 peptides as defined herein. In a particular embodiment, the invention relates to an antigen or peptide or a combination or multimer antigen comprising at least 2 peptides as defined herein suitable for use in a vaccine, wherein said antigens or peptides (i) are derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55-57, 61 and 64-81, more preferably from 1-3, 7, 17 and 64-81; or (ii) comprise, essentially consist of, or consist of a sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104, preferably 82-104.
[0175] In a preferred aspect, the peptide-based vaccine comprises or consists of a combination of peptides as defined herein or a multimer antigen as defined herein. Optionally, the combination or multimer antigen comprises at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides as defined herein. Optionally, at least one of these peptides is selected among the peptides (i) derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-16 and 64- 81, more preferably from SEQ ID NOs: 1-7 and 64-81, or SEQ ID NOs: 1-3, 7 and 64-81; or (ii) comprising, essentially consisting of, or consisting of a sequence selected from the group consisting of SEQ ID NOs: 18-36 and 82-104, more preferably from SEQ ID NOs: 18-25 and 82-104, or SEQ ID NOs: 18-20 and 82- 104.
[0176] Vaccine may also contain a combination of at least two peptides according to the invention or a set of nucleic acids coding for said at least two peptides, for combined, separate or sequential administration.
[0177] In another embodiment, the vaccine may comprise a multimeric antigen comprising at least two antigens or a nucleic acid coding for said at least two antigens.
[0178] In this regard, the vaccine or immunogenic composition according to the invention comprises a combination or a multimeric antigen comprising at least two peptides, for example at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides, wherein said peptides: (i) are derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55-57, 61 and 64-81, preferably from 1-3, 7, 17 and 64-81; and / or (ii) comprise, essentially consist of, or consist of a sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104, preferably from SEQ ID NOs: 82-104.
[0179] In another particular embodiment, the vaccine or immunogenic composition according to the invention comprises a combination or a multimeric antigen comprising 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides, wherein said peptides: (i) are derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55-57, 61 and 64-81, preferably from 1-3, 7, 17 and 64-81; and / or (ii) comprise, essentially consist of, or consist of a sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104, preferably from SEQ ID NOs: 82-104.
[0180] The antigen(s) or peptide(s) may be in various forms such as in free form, polymerized, chemically or physically modified, and / or coupled (i.e., linked) to a carrier molecule. Coupling to a carrier may increase the immunogenicity and (further) suppress the biological activity of the peptide according to the invention. In this regard, the carrier molecule may be any carrier molecule or protein conventionally used in immunology such as for instance KLH (Keyhole limpet hemocyanin), ovalbumin, bovine serum albumin (BSA), a viral or bacterial anatoxin such as tetanus toxin, diphteria toxoid, cholera toxin B, mutants thereof such as diphtheria toxin CRM 197, an outer membrane vesicle protein, a polylysine molecule, or a virus like particle (VLP). Coupling of the antigen(s) or peptide(s) to a carrier may be performed by covalent chemistry using linking chemical groups or reactions, such as for instance glutaraldehyde, biotin, etc.
[0181] In this regard, in a particular embodiment, the vaccine of the invention comprises a peptide of the invention or a combination or multimer antigen comprising at least 2 peptides as defined herein coupled to a carrier protein. In a preferred embodiment, at least one antigen or peptide is coupled to a carrier protein and said antigens or peptides (i) are derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55-57, 61 and 64-81, preferably from 1-3, 7, 17 and 64-81; or (ii) comprise, essentially consist of, or consist of a sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104, preferably from SEQ ID NOs: 82-104. Optionally, at least one of these antigens or peptides is coupled to a carrier protein and is selected among the peptides (i) derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-16 and 64-81, more preferably from 1-7 and 64-81 or 1-3, 7 and 64-81; or (ii) comprising, essentially consisting of, or consisting of a sequence selected from the group consisting of SEQ ID NOs: 18-36 and 82-104, more preferably from 18-25 and 82-104, or 18-20, 25 and 82-104. Optionally, all antigens or peptides are coupled to a carrier protein.
[0182] Optionally, the vaccine or immunogenic composition of the present invention may further comprise one or several helper peptides. The helper peptide can be any suitable peptide that stimulates CD4+ T cell responses that are not specific for cancer antigens, but may stimulate recall responses or other nonspecific help. Activation of CD4 T-cells can support CD8+ T-cell. The helper peptide can be selected among a pan- DR helper epitope (PADRE), a tetanus helper peptide, a hepatitis B surface antigen helper T-cell epitope, a pertussis toxin helper T-cell epitope, a measles virus F protein helper T-cell epitope, a Chlamydia trachomitis major outer membrane protein helper T-cell epitope, a diphtheria toxin helper T-cell epitope, a Plasmodium falciparum circumsporozoite helper T-cell epitope, a Schistosoma mansoni triose phosphate isomerase helper T-cell epitope, a keyhole limpet hemocyanin, a Plasmodium vivax B cell epitope (PVB), a Escherichia coli TraT helper T-cell epitope, a synthetic T helper epitope, immune-enhancing analogs and segments of any of the foregoing helper peptides.
[0183] Optionally, the vaccine or immunogenic composition of the present invention may further comprise one or several additional tumor associated antigens or a nucleic acid encoding them. Such tumor associated antigens are well-known by the person skilled in the art.
[0184] In a further embodiment, the vaccine or immunogenic composition according to the invention further comprises at least one suitable carrier, excipient or diluent as described above. In another particular embodiment, the vaccine or immunogenic composition of the invention further comprises at least one immunostimulatory agent or adjuvant. Such immunostimulatory agents to be used in conjunction with the vaccine of the invention for stimulating antigen specific T cell responses include but are not limited to one or more major histocompatibility complex (MHC) molecules, such as class I and class II molecules, preferably a class I molecule. The vaccine of the invention may also comprise one or more suitable adjuvants including any substance that, for example, activates or accelerates the immune system to cause an enhanced antigen-specific immune response. Optionally, the adjuvant can be a Toll-like receptor agonist, a NOD- like receptor agonist, an Mda5 agonist, a RIG-I agonist, or a STING agonist. Examples of adjuvants that can be used in the present invention include mineral salts, such as calcium phosphate, aluminum phosphate and aluminum hydroxide; immunostimulatory DNA or RNA, such as CpG oligonucleotides; proteins, such as antibodies or Toll-like receptor binding proteins; saponins (e.g., QS21); cytokines which include but are not limited to IL-1 (interleukin- 1) through IL- 15 (interleukin- 15), tumor necrosis factor alpha (TNFa), IFNy (interferon gamma), CCL5 (chemokine C-C motif ligand 5 also known as RANTES), G-CSF (granulocyte colony-stimulating factor), M-CSF (macrophage colony-stimulating factor), CTAP III (connective tissue activating peptide III), CXCL5 (C-X-C motif chemokine 5 also known as ENA-78), PF-4 (platelet factor 4), IP- 10 (interferon-gamma-induced protein 10), MIP-1 (macrophage inflammatory protein 1), ; LPS (lipopolysaccharide); MPL (monophosphoryl lipid A); GM-CSF (Granulocyte- macrophage colony-stimulating factor); imiquimod; colloidal particles; complete or incomplete Freund's adjuvant; Ribi's adjuvant or bacterial toxin e.g. cholera toxin or enterotoxin (LT) or combinations thereof.
[0185] The adjuvant can be a mixture of a hydrocarbon oil with a water-in-oil emulsifier. In particular, the hydrocarbon oil can be selected from paraffin oil, a vegetable oil, squalene, squalane or a mineral oil and the water-in-oil emulsifier can be selected from mannide mono-oleate and sorbitan mono-oleate. In a specific embodiment, the hydrocarbon oil is a mineral oil and the water-in-oil emulsifier is selected from mannide mono-oleate. Examples of appropriate oily adjuvants are a mixture of 5-20% mannide monooleate with 80-95% mineral oil (Montanide® ISA 51 sold by SEPPIC) or squalene (Montanide® ISA 720 sold by SEPPIC) and similar mixtures. In a specific embodiment, the adjuvant is a mixture of mineral oil and mannide mono-oleate, especially Montanide® ISA 51.
[0186] Examples of useful adjuvants include, but are not limited to, poly- ICLC (polyinosinic and polycytidylic acid, stabilized with poly-l-lysine and carboxymethylcellulose), 1018 ISS, aluminum salts, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, Imiquimod, ImuFact IMP321, IS Patch, ISS, ISCOMATRIX, Juvlmmune, LipoVac, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, PepTel.RTM, vector system, PLGA microparticles, resiquimod, SRL172, Virosomes and other Virus-like particles, VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21 stimulon, vadimezan, and AsA404 (DMXAA).
[0187] The immunogenicity of the antigen according to the invention may be tested by various methods, such as by immunization of a non-human animal grafted with human immune cells, followed by verification of the presence of antibodies, or by sandwich ELISA using human or humanized antibodies.
[0188] Administration of an antigen or vaccine of the invention may be by any suitable route, such as by injection, preferably intratumoral, intraperitoneal, intramuscular, subcutaneous, transdermal, intravenous or intraarterial, or by nasal, oral, mucosal or rectal administration. In a preferred aspect, the vaccine is administered through intramuscular or subcutaneous injection.
[0189] The invention may be used in any mammal, particularly in human subjects.
[0190] The peptide or vaccine of the invention is suitable for treating any cancer by inducing or stimulating an antigen-specific immune response, preferably a T-cell specific immune response.
[0191] The peptide or vaccine of the invention is particularly suitable for treating any cancer associated with the DIS3 gene mutation or misexpression, as described herein.
[0192] All the references cited in this description are incorporated by reference in the present application. Others features and advantages of the invention appear in the following examples which are given for purposes of illustration and not by way of limitation.
[0193] EXAMPLES
[0194] MATERIALS AND METHODS
[0195] Cell line and cell culture. Cells were cultured in Me Coy’s 5A (Gibco, 16600-082) medium supplemented with 10% fetal bovine serum (FBS) (Eurobio, CVFSVF0001) at 37°C in a humidified 5% CO2 atmosphere. HCT116:TIR1 cell line constitutively expressing TIR1 was described in (Eaton et al. 2018) and DIS3-AID cell line was described in (Davidson et al 2019). The KMM-1 (JCRB) cell line was grown in RPMI 1640 media (Gibco, 21875-034) and 10% FBS the suspension part of the culture was passaged by dilution while the adherent cells were trypsinized. For construction of XRN1-AID cell line a HCT116 tet-on Tirl cell line was created using protocol and plasmid from (Natsume et al. 2016), following protocol described in Eaton et al. 2018. Briefly, 250.000 HCT116 cells were seeded / well in 6 well plate a day before transfection, lug of gRNA targeting stop codon of XRN 1 plasmid and Homology Directed Repair template containing three tandem FLAG and miniAID epitopes and neomycin selection marker was used for transfection with Jetprime (Polyplus), following the manufacturers’ guidelines. The selection marker was separated from the tag by P2A site for cleaving during translation (Kim et al. 2011). Media was changed after 24 hours and, after 48 hours, cells were re-plated into 100mm dishes in media containing 700ug / ml Neomycin. Resistant colonies were picked after 7 days. Correct genomic insertion of tags was assayed by PCR and by Western blot. For DIS3- AID set of experiments, auxin was used at a concentration of 500uM for 1 hour unless stated otherwise, for XRN1-AID due to need of inducible TIR1 2 pg / ml doxycycline (dox) and 500 pM auxin was added for 24 h.
[0196] CRISPR clone construction. gRNA was cloned into pX459 plasmid (Addgene 62988) using two rounds of PCR amplification of gRNA insert with flanking region containing Aflll and Xbal cloning sites. Next, both PCR product and plasmid were digested and ligated using T4 ligase (NEB) overnight. Proper insert was assayed by sanger sequencing. For homology repair template a plasmid with XRN 1 homology arms (500 nt flanking stop codon form both side, synthesized by GeneScript) and 3xFLAG 3xminiAID Neomycin containing vector constructed in Eaton et al. 2018 was used for amplification of respectful fragments using primers listed in Table 2 for cloning with NEBuilder® HiFi DNA Assembly kit. Obtained vector was assayed by Sanger sequencing and linearized before introducing into cells.
[0197] Cell Fractionation. After de-freezing cells were passed at least 2 times before seeding 2.5x 10A6 cells into T150 flasks and grown to 80-90% of confluency. For XRN1-AID, the auxin and doxycycline were added 24h before reaching this confluency while for DIS3-AID auxin was added for Ih the last day. For each condition cells were grown in 4 flasks from which 1 was used for protein extraction and fractionation control and 3 others for the replicates of RNA. Cells were washed with cold PBS and scrapped in PBS on ice. After gentle centrifugation cell pellet was resuspended in buffer containing a-amanitin, RNase (SUPERasin) and proteinase (complete) inhibitors and low level of detergent to lyse cell membrane and keep the nuclei intact, followed by centrifugation collection of cytoplasmic fraction and lysis of nuclei and separation of chromatin. Described before in Gagnon et al. 2014 (with Tris pH 7.4for HEB and NLB buffer). The quality of separation of the fractions was tested on western blot and by qPCR.
[0198] RNA extraction and qPCR. RNA was extracted using the miRNeasy Mini Kit (Quiagen, 217004) following the manufacturers instruction. An additional DNase (Qiagen) treatment was performed following the manufacturer’s instructions for samples send for sequencing. For testing the cell fractionation same volume of RNA was taken of reverse transcription reaction. For other experiments 500 ng of RNA was used for first-strand cDNA synthesis using SuperScript II RT (Invitrogen) and following the manufacturer’s instructions with 100 ng of random primers (Invitrogen) used for total cDNA synthesis with primers listed in (Table 2). Real time qPCR was performed using SyberGreen (Roche) and Eight Cycler 480.
[0199] Table 2: List of primers used
[0200] Fw: forward; Rev: reverse
[0201] Protein extraction. Beside cell fractionation experiment, protein extracts were prepared from cells grown in plOO plates, washed once with ice cold PBS, and lysed in 500 pl RIPA lysis buffer (ThermoScientific, 89900) supplemented with 10 pl / ml of a protease and phosphatase inhibitor cocktail (ThermoScientific). The lysed cells were scrapped and collected into Eppendorf tube followed by 8min sonication in 30 sec ON / 30 sec OFF cycles (Diagenode) and centrifuged 10 min at 13 000 rpm at 4°C. Protein concentration was analyzed using the Pierce BCA Protein assay kit (ThermoScientific). Antibodies used for Western blot are listed in Table 3.
[0202] Table 3: List of antibodies used
[0203] Ribo-seq. For each of the cell lines, two vials were thawed and followed to obtain two independent biological replicates. Cells were passed at least two times before seeding lxlOA6 cells into plOO dishes. Two days later, on the day of experiment, media were aspirated from the plates and fresh media with or without auxin were added for Ih. Afterwards, media were aspirated and dishes were flash frozen in liquid nitrogen and stored in -80°C for further use. Cells were gently defreezed on ice and 250pl of lysis buffer buffer (lOmM Tris pH7.5; lOrnM (CH3COO)2Mg; lOOmM KC1; 1% Triton; 2mM DTT) containing complete protease inhibitor cocktail (Roche) and 2U of RNase Murine Inhibitor (NEB) was added to each dish. Cells were collected with scrapper and then centrifuged for 3 minutes at maximum speed at 4°C an aliquot of each lysate was collected for RNA extraction and the rest was flash frozen and stored at -80°C. Cell lysates were loaded onto a 24% sucrose cushion centrifugated 90 min at 110 krpm on a TLA110 rotor at +4°C. Next polysomes were rinsed 2 times with 500pl of lysis buffer then resuspended with 500pl of lysis buffer and digested using 5U / UA260nm RNase I (Ambion) for Ih at 25°C followed by addition of 500U of SUPErasin RNase inhibitor (Invitrogen). RNA was extracted by acid phenol at 65°C, chloroform and precipitated by ethanol with 0.3 M sodium acetate pH5.2. Resuspended RNA was loaded on 17% polyacrylamide (19:1) gel with 7M urea and run in IxTAE buffer for 6h at 100V. RNA fragments corresponding to 28-34nt were retrieved from gel and precipitated in ethanol with 0.3 M sodium acetate pH5.2 in presence of lOOpg glycogen. rRNA was depleted using riboPool (siTools), adjusting initial volume to 40ul reaction and adding lul of Murine RNase inhibitor (NEB) to each sample before and after hybridization step. RNA was precipitated and concentration was measured by Qubit (Thermo Fisher Scientific). 10 ng of each sample was engaged in library preparation using D-plex Small RNA-seq Kit (Diagenode) following manufacturer’s instructions with 10 cycles of PCR amplification in the last step followed by DNA purification with Monarch PCR DNA cleanup kit (NEB) and AMPpure XP beads final cleanup. Library molarity was analyzed using Tape Station and an equimolar pool of libraries was sequenced on a NovaSeq 6000 system (Illumina) with 10% PhiX .
[0204] MS IP. For immunopeptidomic, DIS3-AID cell line was amplified in T300 flask to 80-90% confluency and auxin was added for 4h. Next, cells were washed 3 times in ice cold IxPBS and collected by scrapping, followed by centrifugation at 4°C. The cell pellets were flash frozen in liquid nitrogen and stored at -80°C for further use. Two biological replicates were pooled together giving 600mln of cells that were further used for immunopeptidomics. For KMM-1 cell line 5X T300 flasks were prepared for each replicate. Adherent cells were collected as for the DIS 3 -AID and the suspension cells were washed 3 times with cold lx PBS before combining with scrapped cells. Two replicates were prepared with total of around 400M cells. Cells were resuspended in lysis buffer at 4°C. After homogenization, the lysates were cleared by centrifugation and underwent a preabsorption on empty protein A-agarose columns. After this preclearance step, a pull down of the MHO complexes were carried out, using clone W6 / 32 anti-MHCI antibody coupled to the protein A-agarose columns. After multiple washing steps, the MHC complexes are eluted and dissociated in mild acid elution buffer. Immune peptides were separated from other eluted components by reverse phase separation prior to loading on evotips for chromatographic separation by an evosep one HPLC system. An Evosep One LC system was coupled with the Bruker timsTOF Pro mass spectrometer equipped with the Bruker Captive Spray source. The 30 SPD method was used. The Endurance Column 15 cm x 150 pm ID, 1.9 pm beads (EVI 106, Evosep) was connected to a Captive Spray emitter (ZDV) with a diameter 20 pm (1865710, Bruker) (both from Bruker Daltonik GmbH, Bremen). The timsTOF Pro was calibrated according to the manufacturer’s guidelines. The source parameters were: Capillary voltage 1500 V, Dry Gas 3.0 Emin and Dry Temp 180 °C. The temperature of the ion transfer capillary was set at 180°C. Column was kept at 40°C. The Parallel Accumulation-Serial Fragmentation DDA method was used to select precursor ions for fragmentation with 1 TIMS-MS scan and 10 PASEF MS / MS scans, as described by Meier et al. (2018). The TIMS-MS survey scan was acquired between 0.70 and 1.45 Vs / cm2 and 100-1,700 m / z with a ramp time of 100 ms. The 10 PASEF scans contained on average 12 MS / MS scans per PASEF scan with a collision energy of 10 eV. Precursors with 1-5 charges were selected with the target value set to 20,000 a.u and intensity threshold to 2,500 a.u. Precursors were dynamically excluded for 0.4 s. The timsTOF Pro was controlled by the OtofControl 6.0 software (Bruker Daltonik GmbH). Ten PASEF scans can contain up to 12 MS / MS scans per PASEF scan. Data were analyzed MS Fragger, integrated in the FragPipe pipeline(Kong et al. 2017). The build-in “Nonspecific-HLA” workflow was used. Precursor and fragment mass tolerance was set at 20ppm. Oxidation (M), N-terminal acetylation, pyroglutamine, pyroglutamate and cysteinylation were set as variable modifications. The standard database search validation tools from the Nonspecific-HLA workflow were also used, including MSBooster, which is a rescoring tool that uses deep learning predictions of RT fragment intensities (Yang et al. 2022). The FDR of peptide and PSM matches was set 1%. Uniprot human reference proteome database was concatenated with the custom IncRNA ORF database described in the text. smiFISH. For smiFISH experiment, cells were passed at least 2 times after thawing. Two days before experiment, the cells were seeded on coverslips coated with 0.01% poly-L lysin (Sigma) to reach 40-60% of confluency on the day of experiment. At day of the experiment, cells were incubated with fresh media with or without auxin for Ih followed by 2x wash in IxPBS and fixation with 4% PFA (Electron Microscopy Sciences) for 20 min. Next, the slides were washed 2x with PBS followed by addition of cold 70% EtOH and stored at 4°C before hybridization with smiFISH probes. The smiFISH protocol was performed as described in Tsanov et al. 2016. The smiFISH probes were designed using Oligostan (Tsanov et al. 2016). 24 specific probes passing the filters of Oligostan design tool were used for hybridization with fixed cells. The images were taken using Zeiss Axioimager Zl / Apotome) equipped with a 63x objective and a CCD camera (Axiocam MRm). Obtained images were processed and analyzed using FISH-quant v2 python packages (Imbert et al. 2022) for cell segmentation and spot detection. For each image automatic thresholding was used to adapt for variable background levels. Two independent replicates of the experiment were performed with DIS3-AID cell line incubated with or without auxin for Ih. For each replicate at least 100 cells were quantified.
[0205] Analysis of DIS3 mutation impact on protein structure / activity. Initially, the atomic structures available for the DIS3 protein were analyzed, with the position altered residues, with respect to the defined catalytic active sites (Tomecki et al. 2014). Then a systematic analysis of the structural alterations observed for DIS3 in patients was performed, using a combination of the missense3D software (Ittisoponpisan et al. 2019) together with the structural analysis of the available atomic structures of the protein (Weick et al. 2018; Gerlach et al. 2018). The atomic model (PDB 6D6Q) (Weick et al. 2018) was visualized using USCF Chimera (Pettersen et al. 2004).
[0206] Data analysis. Quality control and alignment of RNA-seq and Ribo-seq data: The Curie bioinformatics platform performed the quality control of the RNA-seq and Ribo-seq data using MultiQC. The alignment of the reads to the human genome hg38 was done using STAR 2.6.1a, with the following parameters: - outSAMstrandField “intronMotif” -outSAMattributes “All” -outSAMtype “BAM” “SortedByCoordinate” -alignlntronMax 1000000 -outFilterMismatchNmax 999 -seedPerReadNmax 100000 - outFilterMultimapNmax 20. Multi-mapped reads were filtered-out, and for Ribo-seq alignments, only reads of length 25 to 34 nucleotides were kept for downstream analysis.
[0207] Transcrip tomic profiling. Transcriptome assembly was performed on each RNAseq alignment using Scallop vO.10.5, with the following parameters: -min_transcript_length_base 200 -library_type “first” - min_splice_bundary_hits 5 -min_transcript_coverage 10 -min_single_exon_coverage 20. The obtained GTF annotations of all samples were merged with cuffmerge from cufflinks v2.2.1, then genes for which the exons overlap gencode v26 annotation were filtered out with BEDTools v2.29. The result was finally combined with gencode v26 (https: / / www.gencodegenes.org / human / release_26.html) and eRNAs annotation retrieved from (Lidschreiber et al. 2021) for downstream analysis.
[0208] Premature and intronic RNAs analysis. We performed a separate quantification on exons and intron annotation. The genes that would have only differentially expressed first exon and intron or only introns (Szczepinska et al. 2015; Davidson et al. 2019) were selected. We focused on the gencode annotated RNAs as the unreferenced IncRNAs are mostly monoexonic. All multiexonic transcript types were included in this analysis. Among the upregulated transcripts in our DIS3-AID dependent list, 285 upregulated genes fall into PT definition of which 46 are mRNA and 218 IncRNAs. To confirm this result we visualized a metagene for the PT genes containing at least 2 introns (173 from 285). Importantly transcripts where only intron were significantly upregulated represent 31% of gencode upregulated transcripts (766) with 516 IncRNAs and 219 mRNAs. The metagene of such transcripts clearly show that different introns of the multiexonic transcript are upregulated. This result reduced the number of potential mature mRNAs regulated by DIS3 from 537 to 272 and annotated IncRNAs from 1733 to 999.
[0209] Enhancer RNAs. For eRNA published annotation in HCT116 of conservative eRNA was used (Lidschreiber et al. 2021). We analyzed how many of these annotated eRNA fall into regions of the upregulated genes defined in (Fig. 1). In total, 362 gencode annotated RNAs overlap with the upregulated eRNAs (with at least 1 nt of overlap), including 298 IncRNAs and 27 PCG, and 342 scallop annotated IncRNA. For further analysis those RNAs were classified as eRNAs
[0210] Active ORFs detection. Ribotricer 1.3.1 was used to detect long and short actively translating ORFs. The first step consisted in the generation of all candidate ORFs from the combined GTF annotation (gencode v26, scallop and eRNAs) and hg38 genome, by using the command "prepare-orfs" with the following parameters: -start_codons "ATG, CTG, TTG, GTG, AGG, ACG, AAG, ATC, ATA, ATT" - min_orf_length 30 —longest. The resulting table was converted into GFF by custom command lines. The second step consisted in the use of the command "detect-orfs" to determine translating ORFs from the candidate ORFs for each Ribo-seq alignment. The GFF across all the samples were concatenated and then the redundancies were filtered out based on the following columns of the GFF: chromosome, start, end, strand, attributes. For downstream analysis, ORFs with at least 9 non-zero coverage leading codons were considered strongly active. As the ORF prediction is only based on the annotation, we further tested if the IncRNA ORFs that would span an exon-exon junction would also have such junction present in RNA-seq data in the DIS3 depleted conditions. To be sure that the ORF is translated from DIS3 -sensitive isoforms of transcripts we have performed quantification of RNA-seq data on the ORF annotation followed by recursive analysis as for RNA-seq and only the ORFs that would be differentially expressed in the RNA- seq data for both gene and ORF annotation were retained as IncRNAs predicted to be translated upon DIS3- depletion. We have observed a peak from Ribo-seq on the snoRNA location in the snoRNA host genes, thus to remove bias that could come from the snoRNA we eliminated the genes that the name would contain SNHG, SNO, SNU or RNU and one eRNA that also showed high peak from snoRNA. For Ribo-seq. in total we obtained between 3 and 79 millions of reads per sample. Due to variable number of reads between the replicates we have selected ORFs that would be assigned as actively translated in at least one replicate and at least detected in the second replicate of each condition.
[0211] Read counting and differential expression. Read counting on gene, exon, and ORF levels were performed on the combination of the human gene annotation gencode v26, eRNAs, and new transcripts from scallop, using featureCounts v2.0.0 with the parameters -s 2 -O. Analyses for Fig. 1 were done using gencode annotation for normalization of DESeq2 data for unreferenced genes. For further quantifications, modified annotation including eRNA and scallop transcripts was used. The conditions were compared using DESeq2, with the following parameters: betaPrior=FALSE, independentFiltering=F, cooksCutoff=F. Only the features with adjusted p-value <= 0.05, read counts >=20 and abs(log2FoldChange)>= 0.585 were retained as differentially expressed. Heatmaps of expression were obtained using the R package ComplexHeatmap from bioconductor.
[0212] Recursive analysis. For the gene to be retained in the final list, it had to be differentially expressed in the same direction in both control + versus tagged cells + but also between tagged cells - versus tagged cells +, if in the latter the same gene was not differentially expressed between control cells - versus control cells +. For XRN1-AID dataset first comparison: control + versus clone + and clone - versus clone + was performed for each clone independently and intersected with addition of genes differentially expressed for both clones in only comparison of clone - versus clone + but not in control cells - versus control + was retained in the list.
[0213] Metagenes. In order to select the wanted parts (exons and introns), we have created firstly metatrancripts as follows: the exons from all the transcripts of each gene were merged with BEDTools v2.29, in order to have non-redundant segments of exons, and these exons were numbered; introns were inferred from these exons. The first exon, first intron, second exon, last intron and last exon were selected for each gene. The alignment files were converted in BigWig files with RPM normalization (reads per million of mapped reads), using UCSC tools (http: / / hgdownload.cse.ucsc.edu / admin / exe / linux.x86_64 / ), and for each part and each gene, the read coverage was extracted. The obtained signal was scaled on 100 positions using the R base approx function (allows to compute interpolations), with the following parameters: method="linear", ties="ordered". The average value was computed at each of the 100 positions, and the result was plotted using the R package ggplot2.
[0214] Refining TSS and TES. For better definition of the start and end of our candidates that do not follow fully the standard annotation, we used a sliding window approach of 200nt. For a given gene, the sliding window is run on the metatranscript of exons only (successively from the start to determine the new start, and from the end, to determine the new end); if the first 200nt have non-null read coverage values across Dis3_A samples, the original start or end is kept, otherwise, the window is slid until a minimum coverage of 5 reads inside the window is found, then the most upstream new start or the most downstream new end is reported. If no new start or new end can be reported, we use the same method, but on the gene level (the new start or new end can be in the introns in this case). Refined candidates with a length less than 200nt are re -processed with the sliding window approach at the gene level, but to find at the same time the new start and new end (as the steps above can fail for candidates with short exons and read coverage spanning the introns). After start and end refining, candidates with a length below 200nt are removed.
[0215] Transcript bidirectionality analysis. The division of DISTs to upstream antisense (ua) RNAs, convergent (con) RNAs and bidirectional eRNAs was performed as defined in Lidschreiber et al. 2021. For eRNA all the pairs, where at least one eRNA would be upregulated, were taken resulting in 777 bidirectional eRNA.
[0216] Conservation analysis. To analyze conservation of sORFs, an amino acid sequence of each of the differentially expressed ORFs in DISTs was selected for analysis and queried with blastp version 2.9.0 (NCBI) against a protein sequence retrieved from 120 mammalian species (Hecker and Hiller 2020). The hits that had at least 20% overlap and 20% identity were retained for plotting the conservation.
[0217] HLA binding prediction. HLA alleles from MM patients were determined using the tool seq2HLA. ORFs candidates were converted into peptides using the SeqinR R package, and only the ones with a length >= 8 amino acids were kept. The lists of peptides and HLA alleles were given to the tools NetMHCpan-4.1 and NetMHCIIpan-4.0 in order to determine the binding status. Only the peptides with an elution ligand rank <= 2 were kept for downstream analysis.
[0218] Patients Data. The data concerning patients samples were previously published (Hdllein et al. 2020). New counting on the raw reads was performed using kallisto (Bray et al. 2016). All further analysis followed the standard DESeq2 protocol. RESULTS
[0219] Example 1. System for studying cytoplasmic RNA surveillance
[0220] To short list the potential enzyme that could regulate IncRNAs decay in cytoplasm we first looked on already published datasets for different degradation cofactors and performed differential expression analysis (DEseq) with the latest version of gencode annotation. We have selected a XRN 1 knock out dataset from HEK293 cells (Chang et al. 2019), deep sequencing of DIS3 mutants with inactivated RNB and PIN domains (Szczepihska et al. 2015), EXOSCIO depletion data (Davidson et al. 2019) and HBS1LV1, HBS1LV3 and SKIV2L knock downs. Among all of the analyzed datasets, DIS3 double mutant of RNB and PIN domain showed the highest number of upregulated IncRNAs, with 5611 upregulated IncRNAs. The second set was represented by XRN1 knock out in line with 612 stabilized IncRNA. EXOSCIO depletion resulted in only 3 stabilized IncRNAs. Knock down of the cytoplasmic cofactors of exosome, binding also DIS3L protein- HBS1LV1, HBS1LV3 and SKIV2L, resulted in upregulation of 231, 317 and 69 IncRNAs, respectively. Thus, we focused our study on DIS3 and XRN1 enzymes showing the highest number of impacted IncRNAs.
[0221] To understand which of the two exonuclease could play specific role in degradation of cytoplasmic IncRNAs, we performed cellular fractionation (Gagnon et al. 2014) and isolated total cytoplasmic RNAs from cells depleted of DIS3 or XRN1 exonucleases. We hypothesized that prolonged treatment with siRNA or several passages of cells with a knocked out, could cause cell adaptation and buffering or indirect changes in RNA levels. Thus, it would not reflect direct effect of the RNA decay machinery depletion. Therefore, we opted for an auxin inducible degron system enabling a rapid depletion of the analyzed enzymes (Nishimura et al. 2009). In this system AID tagged protein is recognized by auxiliary introduced plant E3 ubiquitin ligase, Tirl that upon addition of indole-3-acetic acid (referred to here as auxin [IAA]) leads to degradation of tagged protein (Fig. 1 A). DIS3-AID cell line was already described in Davidson et al. 2019 and we constructed the XRN1-AID HCT116 cell line with Tirl under Tet-On promoter to reduce non induced degradation (as described above in 'Materials and methods’).
[0222] Cell lines expressing DIS3-AID and XRN1-AID were checked by Western blot and showed lower levels of the proteins in comparison to control cells, after addition of auxin during Ih (Fig. IB) or auxin and doxycycline 24h, respectively (Fig. IB). No significant effect on cell growth was observed for novel XRN1- AID cell lines in standard conditions. To ensure that observed effects on RNA level come from the direct manipulation of XRN 1 level and not off target of gRNA two independent clones were used for further experiments.
[0223] After the designated depletion times, triplicate of cells cultures for each condition were subjected to fractionation protocol that enables separation of cytoplasm from nuclei. The quality of the fraction was tested by Western Blot with specific nuclear and cytoplasmic proteins as well as by RT-qPCR level on the RNA samples. Cytoplasmic RNA from all the samples were used to prepare total stranded RNA seq libraries after depletion of ribosomal RNAs. For both data sets XRN1-AID and DIS3-AID between 54-112 million of uniquely mapped reads to human genome version 38 were used for further analysis to determine changes in cytoplasmic RNA levels.
[0224] Example 2. XRN1 and DIS3 exonucleases regulate distinct classes of cytoplasmic RNAs
[0225] Since DIS3 and XRN1 are exonucleases targeting cryptic transcripts in human and yeast respectively, we used both standard gencode v26 annotation of full transcripts and profiling of the read counts, using the scallop reference-based transcript assembler (Shao and Kingsford 2017), to define non-referenced IncRNAs. Only novel transcripts falling into intergenic regions or antisense to annotated transcripts with lengths of at least 200nt were retained from the prediction. The differential expression analysis using DESeq2 (Love et al. 2014) and threshold of absolute log2 fold change >0.585 showed that both enzymes’ depletions altered a significant number of genes with 5 327 and 1 962 for DIS3-AID and XRN1-AID, respectively, among which 3 630 and 1 426 are upregulated. Assuming the direct effect of exonuclease inactivation would be the stabilization of transcripts, we focused on the upregulated genes only for further analyses. Importantly, among the upregulated genes in XRN1-AID, 77% represented mRNAs while for DIS3-AID, almost 77% fell into non-coding RNA regions, with 1733 annotated and 1048 unreferenced IncRNAs, indicating distinct RNA targets of the two enzymes. Among the unreferenced IncRNAs for DIS3, 334 had PROMPT characteristic- non-TSS overlapping and antisense transcript in up to 2.5kb upstream TSS. Xrnl inactivation showed only 159 annotated and 10 unreferenced upregulated IncRNAs, suggesting that XRN1 has a limited role in IncRNA regulation. Only 87 IncRNAs were common with XRN1-AID data (p-value=2.7e-308 of the overlap, tested Fisher's exact test (alternative=greater)), among 276 IncRNAs expressed in both cell lines and upregulated in XRN 1 KO. This reinforces the idea that XRN 1 is mostly dedicated to coding genes degradation in human cells.
[0226] Concerning DIS3-AID, in addition to the full transcripts differential analyses, we filtered out genes showing differential expression within the first exon and first intron or within introns only, a signature of prematurely terminated (PT) transcripts and DIS3 sensitive unstable transcripts ).
[0227] The list of remaining DIS3 sensitive IncRNA annotated in gencode containing at least 2 introns (424) was used to plot a coverage metagene and compared to the 66 multi -intronic IncRNAs upregulated in XRNL Interestingly, our results showed that the accumulated IncRNAs and mRNAs after XRN1 depletion are mostly spliced, enforcing XRN 1 role in processed RNAs surveillance in cytoplasm The accumulation of the last exon could be related to the dynamic of degradation process in which XRN 1 mostly stalls at the 3 ’ end of transcripts as previously shown (Tuck et al. 2020). Surprisingly, even though we filtered out the premature transcripts and IncRNAs containing only intronic reads, the metagene for DIS3-sensitive cytoplasmic IncRNAs and mRNAs still showed accumulation on both exons and introns, suggesting that the DIS3-sensitive transcripts either are broadly unprocessed or DIS3 substrates are not well annotated.
[0228] To identify the characteristics of DIS3-sensitive IncRNAs, we compared the accumulated IncRNAs with enhancer RNAs, known to be a natural targets of DIS3, using the recently published annotation of eRNA based on TT-seq and characteristic chromatin marks in HCT116 (Lidschreiber et al. 2021). Quantification of reads on the conservative eRNA annotation based on our recursive analysis and same filters as for the standard DE-Seq2 led to identification of 3025 upregulated eRNAs in DIS3 depleted conditions giving a total of 5166 DIS3-sensitive IncRNAs (DISTs) accumulated in the cytoplasm (Fig. 1C).
[0229] In conclusion, our analysis showed that DIS3 is the main pathway that prevents accumulation of IncRNA within the cytoplasm, in contrast to XRN 1 that targets mostly mRNA.
[0230] Example 3. DIS3-sensitive cytoplasmic transcripts share many features with nuclear DIS3-targets
[0231] DIS3 is responsible for regulation of unstable transcripts in the nucleus (Davidson et al. 2019; Szczepihska et al. 2015; Tomecki et al. 2010), thus we wanted to further understand how many stabilized transcripts are shared by both cellular compartments. We re-analyzed data for DIS3 nuclei-seq done on the same cell line using our combined annotation. We compared the DIS3-AID cell line with and without treatment and identified 5336 upregulated nuclear IncRNAs with log2FoldChange>0.585 including 2884 eRNAs and 697 scallop annotated IncRNAs. After intersection with the data from CYTO-seq we have found 4135 commonly upregulated IncRNAs. Thus, we looked also if the selected IncRNAs followed the characteristic features of nuclear targets of exosome that are often a result of bidirectional transcription. We refined the start and stop position for our IncRNAs and eRNA based on sliding window approach to adapt the annotation to the reads detected in our cyto-seq (as detailed in ’Materials and methods’). The 5162 RNAs that passed the 200nt filter, were further analyzed in regards of bidirectionality of transcription. We divided the groups of DISTs accordingly to upstream antisense (ua) RNAs, convergent (con) RNAs and bidirectional eRNAs as defined in (Lidschreiber et al. 2021). Our results showed 797 bidirectional eRNA, 1157 ua- and con-RNAs in a promoter region of PCGs. In total, -38% of the upregulated IncRNA follow RNA Pol II- dependent bidirectionality. When we analyzed different features of the differential IncRNA and eRNA against other IncRNAs and PCG the most evident criteria that was distinct from the two other groups was the shorter length of the DISTs on the full transcript level (p-value<0.001 in two sided t-test). Simultaneously, when we compared only the exon length, the DIST-exons were significantly longer than the other IncRNAs and PCGs. Both results are strongly related with the fact that in majority DISTs are monoexonic. To better understand the dynamics of the DISTs in the different compartments, we have selected one of the upregulated RNAs present in both analysis CYTO-seq and nuclei-seq and had the characteristic bidirectional transcription CTD-237103.3 in LNCipedia (Volders et al. 2019). Our results showed that nontreated cells contained 6-8 RNA molecules depending on the replicate of the experiment, whereas cells treated with auxin showed a dramatic increase to 49-52 RNA molecules. Importantly, the cytoplasmic presence of the CTD-237103.3 increased by around 2 fold [from 4-7 mean values to 11] post auxin treatment.
[0232] In conclusion, most of the DISTs in the cytoplasm are also detected accumulating in the nucleus, showing that DIS3 inactivation led to some sort of leakage of these transcripts to the cytoplasm but not excluding that DIS3 can degrade the same RNAs both within the nucleus and cytoplasm, raising the question of their cytoplasmic fate.
[0233] Example 4. DISTs can be bound by ribosomes with a characteristic active translation pattern.
[0234] To identify whether and which of the DISTs can be associated with ribosomes, we performed a polysome fractionation followed by RNasel digestion, removal of ribosomal RNAs from ribosome protected fragments (RPFs) and, finally, preparation of the NGS libraries (Fig. 3A). After alignment, only uniquely mapped reads of length 25 to 34 nucleotides were kept for downstream analysis. For detection of actively transcribed open reading frames (ORFs), we used ribotricer, classifying ORFs as actively translated, based on the ribosome periodicity. Knowing that non-canonical coding sequences CDS could start from non- AUG start codon (Chen et al. 2020; Slavoff et al. 2013), we included all 9 possible non-canonical starts such as CTG, TTG, GTG, AGG, ACG, AAG, ATC, ATA or ATT, as described by Ingolia et al. 2011. In total, 431844 ORFs were detected across all conditions to be actively translated in at least one sample. First, to further validate the prediction, we have selected the highest expressed ORF for each of 13711 mRNAs with detected ORFs in Ribo-seq. Metagene spanning 50nt before and after start and stop codons of the mRNAs for the DIS3-AID cell line, showed a characteristic peak of stalled ribosomes just before the start and stop codons with the following reads showing characteristic periodicity of actively translated ORFs (Fig. 2B). Next, to identify the IncRNAs that would be translatable upon DIS3 depletion, we have selected ORFs that would be predicted as actively translated in at least one replicated of samples of DIS3-AID cell line after auxin and removed snoRNA host genes and IncRNAs overlapping PCGs to not have any ambiguity. We identified 750 IncRNA that would contain at least one ORFs predicted to be actively translated in DIS3 depleted cells, further called as translatable DISTs. The metagene of the highest expressed ORF per IncRNA also showed similar characteristic peak of ribosomes stalling around start and stop codons of the ORF (Fig. 2C). To identify ORFs in IncRNA specifically associated with ribosomes upon DIS3 depletion, we intersected the list of all predicted ORFs in IncRNAs for all 4 conditions, eliminating any ORF overlapping snoRNA and PCG to increase stringency of our analysis (Fig. 2D). 1014 ORFs within IncRNAs were identified only in the DIS3 -depleted cells, while 400 are predicted to be actively translated even when the active exosome is present in the cells. This suggests that some of those ORF harboring RNAs might escape exosome-dependent degradation and might be translated in normal conditions. To further define which of our IncRNAs were reported previously to contain ORFs or produce peptide, we compared our prediction with two databases. SPENCER database is dedicated to small peptides encoded by noncoding RNAs in cancer patients (Luo et al. 2022) and we identified 48 ORFs coming from DISTs, with 100% query coverage and identity, originating from 24 IncRNA genes. TransLnc database combines different information of direct and direct evidence of IncRNA translation, based on the gene name we have identified 54 IncRNAs from translatable DISTs. Finally, in a recent annotation of sORFs for gencode (Mudge et al. 2021), 74 DIST genes were also listed to contain a sORF. In all, this indicate that DISTs can be translated in different cellular contexts.
[0235] Next, our rationale was to investigate elements that might control DIST’s translation. We selected the highest expressed ORF of each of 750 translated DISTs and compared with non-differentially expressed translated PCGs and IncRNAs. As expected for IncRNAs, the ORF size is significantly shorter than for PCG with a median value of 138 and 132 nucleotide for IncRNA and eRNAs respectively in comparison to 666 nt for PCGs (Fig. 2E), however both eRNAs and IncRNAs’ ORFs were statistically significantly longer (p-value<0.001) than for other non-differentially expressed translatable IncRNAs with median length of 105 nt. There was no significant difference for the length of 5’UTR between the eRNAs and the two non-differential groups of RNA. However the IncRNAs-DISTs had significantly shorter 5’UTR in comparison to all other groups (Fig. 2F). The sORFs of eRNAs are indifferent from the IncRNAs regulated by DIS 3, thus the difference in UTRs length is directly related to the fact that eRNA transcripts are longer then IncRNA-DISTs. Moreover, the 3’UTRof all IncRNAs differential and non-differential are longer than PCGs that distinguish this class of translated genes (Fig. 2G).
[0236] Poly A tails of transcripts can play important role in their translation , while not all exosome targets are polyadenylated. To understand how many of CYTO-seq identified IncRNAs can be polyadenylated, we performed classical polyA enriched RNA-seq on cytoplasmic RNAs. After crossing the recursive analysis of differentially expressed genes among all the DIS3 -sensitive IncRNAs, only 24% were also significantly upregulated in the polyA-RNAseq, suggesting that polyA tail is not required for the cytoplasmic localization of DISTs after exosome depletion. In contrast, when we focused on the list of 750 translatable DISTs, 54% of them where upregulated in polyA enriched RNA-seq, indicating that the polyA tail would favor translation of the DISTs but is not a prerequisite. For some of the RNAs both the polyA enriched and depleted transcripts can be present in the cells in different proportions. Using density plot, we have identified that only for 422 of all upregulated DISTs, the polyA level was higher than the level in total RNA-seq in DIS3 depleted cells and only for 65 from translatable DISTs, showing that only a minor fraction of those transcripts is mostly polyadenylated . Interestingly, when we compared the transcript length, the
[0237] DISTs that were upregulated in polyA+ RNA-seq were significantly longer than the other DISTs (Fig. 2G).
[0238] To further understand functional relevance of identified sORFs, we checked their conservation in the 120 available mammalian species based on the overlap of protein coding amino acid sequence and identity with filter of 20% for both. In total 109 sORFs in 95 IncRNAs were identified as conserved . Importantly 93% of these IncRNAs were also present in the polyA RNA-seq (Fig. 2H) and 59% were detected as upregulated, suggesting that these RNAs share more features of PCGs than other DISTs (Fig. 21).
[0239] Altogether, we have identified a set of translatable IncRNAs containing mostly sORFs and for 80% of them at least some fraction can be detected in the polyA enriched RNAseq, suggesting that the polyA tail could be one of the elements important for their translation.
[0240] Example 5. DIS3-sensitive cytoplasmic IncRNAs are detected in Multiple Myeloma patients
[0241] As sORFs from IncRNAs could also produce peptides with immunogenic properties, we ask the question of whether cancer, as MM, with recurrent mutations in DIS3 that impacts its activity in vitro, could be a candidate to use DIST as therapeutical target. We first retrieved total RNA-seq data of cohort of 211 multiple myeloma patients and 64 bone marrow samples from healthy control (Hdllein et al. 2020) together with information of the DIS3 mutation status. Using kalisto, custom merged annotation of standard gencode, eRNAs and and scallop-identified transcripts was used to quantify the DIST expression in each patient.
[0242] From the analysis of data from Szczepihska et al. 2015, the RNB domain was the most important for degradation of DISTs. To sub select the patients that could accumulate DISTs because of impaired DIS3 activity, we produced a repertoire of all the mutations and single nucleotide polymorphisms present in DIS3 gene among patients (33 patients), to define those that might affect RNB domain conformation and structure. Using published structure of DIS3 (Weick et al. 2018) and missense3D software, every mutations that could impact the DIS3 structures were identified (depicted the Fig. 3A, listed in Table 4).
[0243] Table 4: List of mutations impacting or not the DIS3 structures
[0244] PDB: protein database; RNB: Exonucleolytic RNase II / R domain ; PIN- endonucleolytic activity via the PilT N- terminal
[0245] We sub selected 15 patients for which the mutation could potentially impair RNB domain activity, group that was named as the DIS3- mutated (excluding the truncated protein). We performed DE-seq analysis comparing the data between DIS3- mutated group, the other patients and the subgroup of samples with DIS 3 -mutations against healthy control. After cross comparing with data obtained from our cell line model, we identified 849 common IncRNAs that were upregulated in all 3 conditions (statistically significant overlap in Super Exact test analysis) (Fig. 3B), for which 203 have an active translated ORFs in our cell line model. To confirm that the ORFs of those IncRNAs were also differentially expressed in the MM samples, only reads falling into the ribotricer-defined ORF were retained to define DIST-ORF upregulated in DIS3-mutated samples versus healthy control, corresponding to 61 transcripts (Fig. 3C) containing 66 differentially expressed sORFs.
[0246] One of the key aspects of specific cancer expressed peptides is that they could be used for therapeutical targets or signature of the cancer cells or aggressive tumors. Here, we investigated whether the MM patients DISTs-derived peptides could have a potential to be presented by the MHC I complex and be a part of tumor specific antigens (TSA). We performed a bioinformatic prediction of binding affinity of the 66 upregulated DIST-ORFs using NetMHCpan-4.1 and NetMHCIIpan-4.0 (Reynisson et al. 2020; Hoof et al. 2009). Surprisingly, for all 66 ORFs, there was at least one 8-14 amino acid peptide sequence predicted to be a strong binder of at least one allele of MHO complex. Thus, to detected DISTs-derived peptides presented by MHO, we used our cell line model, using cells treated 4h with auxin, to increase the residency of DISTs in cytoplasm and probability to be translated. Using the antibody for MHO class I complex purification and analysis of eluted peptides on, unraveled a total number of 5220 peptides. To include all possible peptides coming from our IncRNA candidates we have created a database of ORFs coming from all the ORFs predicted to be actively translated in DIS3-AID cells after auxin and ribotricer prediction of ORF based only on the IncRNA sequence from remaining 638 IncRNAs that were upregulated in cell line and patients’ data. The data analysis using MS Fragger (Kong et al. 2017) of obtained spectra against our DISTs database with the Swissport catalogue identified 8 unique peptides with FDR 1% and probability of above 0.9, coming from DISTs. To assess the robustness of identified peptides we compared the observed retention time (RT) to the RT calculated by DeepEC algorithm (Bouwmeester et al. 2021) based on the peptide sequences. For both protein database and IncRNA peptides the Person correlation was above 0.98 and there was no significant difference (F-test) between standard proteome and IncRNA peptides showing the high quality of the identification (Fig. 3E). Interestingly 2 of peptides were mapped to multiple ORFs from the DIST database while two of the six unique IncRNA ORF-derived peptides came from sORFs detected to be translated by the Ribo-seq experiments in control and DIS3- depleted cells. To further confirm that the IncRNA derived peptides clustered with HLA alleles specific to the HCT116 model cell line, we performed Gibbs clustering (Andreatta et al. 2017). From 5218 peptides identified in the IP 5053 were assigned to one of 4 clusters with the best score between different cluster numbers. After comparison of the identified motifs, all four contained the HLA alleles present in the HCT116 cell line. Two of the IncRNA peptides detected in Ribo-seq were in cluster assigned to HLA-A02:01 while the other to HLA- B45:01. These data confirmed that we can detect translation products from DIST in living cells.
[0247] To not miss any potential TSA candidates we kept both sets of ORFs coming from Ribo-seq and IP for querying the GTEx healthy tissue database and for identifying IncRNA ORFs specifically expressed only in patients with MM. We used our extended sORF annotation for kallisto indexing (Bray et al. 2016) for counting of expression in both our MM dataset and GTEx tissue samples. We used the 90th percentile values and TPM<1 to define a TSAs. Based on such filtering, we identified one DIST sORF detected by the IP experiment and 16 detected from the Ribo-seq (Fig. 3G).
[0248] Example 6. Additional data and analysis performed for the identification of candidate ORFs producing Tumor Specific Antigens.
[0249] In this study, the additional factor of Variant Frequency (VAF) was taken into account to better estimate the impact of the DIS3 mutation, in tumor samples from the multiple myeloma (MM) cohort. The DIS3 mutation VAF estimation resulted in reclassification of the patients data and in a novel differential expression analysis. To extend the potential application of the identified TSAs, we focused on the shared long non-coding (Inc) RNAs that were upregulated in our cell line model inactivated for DIS3 enzyme and in patients cases with DIS3 mutations predicted to impact its activity (Fig. 4). Among the shared upregulated IncRNAs, we identified 329 genes with 469 differentially expressed ORF sequences, that were previously identified as translated in our ribosome profiling experiments.
[0250] We identified 23 ORFs (see Fig. 5 and Table 5), for which the RNA have been detected as polyadenylated and have counts above or equal 1 of 90thpercentile in the MM cases with DIS3 mutation (shown in Fig. 5 as “MM DIS3mut”), as well as counts below 1 for the bone marrow samples (shown in Fig. 5 as “Healthy”) and other healthy tissues from GTEx database except testis (see Fig. 5). This comparison was further enriched by a set of samples from healthy Peripheral blood mononuclear cells (PBMCs) not included in the GTEx database, to further demonstrate the specificity of expression coming from the tumour environment and not the specific tissue, i.e. the normal blood (Fig. 5). The adapted parameters of the analysis enabled identification of 23 ORFs that show> 90% of percent discrimination against all healthy controls and all encode peptides predicted by NetMHCpan-4.1 as strong binder (Table 5). In conclusion, the classification of 23 preferential sequences was based on: (i) the number of potential strong binding pairs of HLA-peptide for the all possible HLA alleles and peptides variants from the given ORF sequence, (ii) the prioritization of peptides binding to the most frequent HLA alleles among European population, and (iii) the high fold changes and levels of expression in the MM patients cases with DIS3 mutation. We gave priority to ORFs that were not described in open access ORF databases, leading to the 23 preferred sequences of Figure 5.
[0251] To further confirm the presence of peptides bound by the MHC-1 complex in the MM specific context, we performed additional immunopeptidomic analyses in MM model cell lines and identified different peptide isoforms coming from ORF No. 17 (Table 5). These peptides were identified in KMS26 cell line and one example of a high-quality spectra is presented in Fig. 6 for the peptide of SEQ ID NO: 37. To further prove the potential therapeutic application of the identified TSA peptides, we ordered the corresponding synthetic peptides and performed in vitro experiments using easYmer - peptide receptive HLA class I (HLA-I) molecules. Flow cytometry-based assay of peptide HLA-I complex formation confirmed the capacity of the identified TSA peptides for efficient binding to HLA-A*02:01 , one of the most common alleles in European population (see Fig. 7, as exemplified for the peptide of SEQ ID NO: 37), thus confirming the therapeutic application for the claimed peptides.
[0252] Table 5: List of selected ORF sequences from IncRNAs and of optimal TSA peptides. The mean expression was calculated based on the differential expression analysis of the RNA-seq data from bone marrow samples from 14 MM patients with the mutation in DIS3 (“MM DIS3mut”) predicted to impair it’s activity and the healthy bone marrow samples (“Healthy”) from the same cohort, and respective fold change was calculated based on the difference of “MM DIS3mut” vs “Healthy”. Quantification was done on the region of ORFs. All the peptides of Table 5 are MHC I-binding peptides.
[0253] In summary, using different experimental models (such as the DIS3 -depleted cell line model, MM cell lines or MM patients data), the inventors were able to identify specific ORFs included in the translated DIS3- sensitive IncRNAs. The inventors have also identified several particular tumor specific peptides among these translated ORF sequences, that have a very strong affinity for MHC / HLA Class I or II, and that may be used as therapeutic targets for treating cancer.
[0254] REFERENCES
[0255] Andreatta M, Alvarez B, Nielsen M. 2017. GibbsCluster: unsupervised clustering and alignment of peptide sequences. Nucleic Acids Res 45: W458-W463.
[0256] Apcher S, Daskalogianni C, Lejeune F, Manoury B, Imhoos G, Heslop L, Fahraeus R. (2011). Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. Proc Natl Acad Sci U S A 108: 11572-11577.
[0257] Bonello, F., Grasso, M., D’Agostino, M., Celeghini, I., Castellino, A., Boccadoro, M., Bringhen, S. (2020). The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Pharmaceuticals, 14, 20.
[0258] Bouwmeester R, Gabriels R, Hulstaert N, Martens L, Degroeve S. 2021. DeepLC can predict retention times for peptides that carry as-yet unseen modifications. Nat Methods 18: 1363-1369.
[0259] Boyle EM, Ashby C, Tytarenko RG, Deshpande S, Wang H, Wang Y, Rosenthal A, Sawyer J, Tian E, Flynt E, et al. (2020). BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clin Cancer Res 26: 2422-2432.
[0260] Bray NL, Pimentel H, Melsted P, Pachter L. 2016. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 34: 525-527.
[0261] Chen, J., Brunner, A.-D., Cogan, J.Z., Nunez, J.K., Fields, A.P., Adamson, B., Itzhak, D.N., Li, J.Y., Mann, M., Leonetti, M.D. (2020). Pervasive functional translation of noncanonical human open reading frames. Science 367, 1140-1146. 10.1126 / science.aay0262.
[0262] Carlevaro-Fita, J., Lanzos, A., Feuerbach, L., Hong, C., Mas-Ponte, D., Pedersen, J.S., PCAWG Drivers and Functional Interpretation Group, Johnson, R., and PCAWG Consortium (2020). Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol 3, 56. 10.1038 / s42003-019-0741-7.
[0263] Davidson, L., Francis, L., Cordiner, R.A., Eaton, J.D., Estell, C., Macias, S., Caceres, J.F., and West, S. (2019). Rapid Depletion of DIS3, EXOSCIO, or XRN2 Reveals the Immediate Impact of Exoribonucleolysis on Nuclear RNA Metabolism and Transcriptional Control. Cell Rep 26, 2779-2791.e5. 10.1016 / j.celrep.2019.02.012.
[0264] Gagnon KT, Li L, Janowski BA, Corey DR. 2014. Analysis of nuclear RNA interference in human cells by subcellular fractionation and Argonaute loading. Nature Protocols 9: 2045-2060. Garfall, A.L., and Stadtmauer, E.A. (2016). Cellular and vaccine immunotherapy for multiple myeloma. Hematology Am Soc Hematol Educ Program 2016, 521-527.
[0265] Hollein, A., Twardziok, S.O., Walter, W., Hutter, S., Baer, C., Hernandez-Sanchez, J.M., Meggendorfer, M., Haferlach, T., Kern, W., and Haferlach, C. (2020). The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time? Cancer Genet 242, 15-24. 10.1016 / j.cancergen.2020.01.001.
[0266] Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, Buus S, Nielsen M. 2009. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 61: 1-13.
[0267] Ingolia NT, Brar GA, Stern-Ginossar N, Harris MS, Talhouarne GJS, Jackson SE, Wills MR, Weissman JS. 2014. Ribosome Profiling Reveals Pervasive Translation Outside of Annotated Protein-Coding Genes. Cell Rep 8: 1365-1379.
[0268] Klinger M, Pepin F, Wilkins J, Asbury T, Wittkop T, Zheng J, Moorhead M, Faham M. (2015). Multiplex identification of antigen-specific T cell receptors using a combination of immune assays and immune receptor sequencing. PLoS One 10:e0141561.
[0269] Kong AT, Leprevost FV, Avtonomov DM, Mellacheruvu D, Nesvizhskii Al. 2017. MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. Nat Methods 14: 513— 520.
[0270] Lidschreiber K, Jung LA, von der Emde H, Dave K, Taipale J, Cramer P, Lidschreiber M. 2021. Transcriptionally active enhancers in human cancer cells. Mol Syst Biol 17: e9873.
[0271] Martino, M., Canale, F.A., Alati, C., Vincelli, I.D., Moscato, T., Porto, G., Loteta, B., Naso, V., Mazza, M., Nicolini, F. (2021). CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. Cancers 13, 2639. https: / / doi.org / 10.3390 / cancersl3112639.
[0272] Nishimura K, Fukagawa T, Takisawa H, Kakimoto T, Kanemaki M. 2009. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nature Methods 6: 917-922.
[0273] Othoum G, Coonrod E, Zhao S, Dang HX, Maher CA. (2020). Pan-cancer proteogenomic analysis reveals long and circular noncoding RNAs encoding peptides. NAR Cancer 2: zcaa015.
[0274] Pertesi M, Vallee M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foil M, Chen S, Perrial E, et al. (2019). Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia 33: 2324-2330.
[0275] Rajkumar, S.V., Kumar, S. (2020). Multiple myeloma current treatment algorithms. Blood Cancer J. 10, 1- 10. Reynisson B., Alvarez B., Paul S., Peters B., Nielsen M. (2020). NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48(Wl):W449-W454.Richard, S., Jagannath, S., Cho, H.J., Parekh, S., Madduri, D., Richter, J., Chari, A. (2021). A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed / refractory multiple myeloma. Expert Rev. Hematol. 14, 31-45.
[0276] Robinson SR, Viegas SC, Matos RG, Domingues S, Bedir M, Stewart HJS, Chevassut TJ, Oliver AW, Arraiano CM, Newbury SF. (2018). DIS3 isoforms vary in their endoribonuclease activity and are differentially expressed within haematological cancers. Biochem J 475: 2091-2105.
[0277] Shao M, Kingsford C. 2017. Accurate assembly of transcripts through phase-preserving graph decomposition. Nat Biotechnol 35: 1167-1169.
[0278] Sheikh, S.; Lebel, E.; Trudel, S. (2020). Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. Future Oncol. 16(34):2783-2798. doi: 10.2217 / fon-2020-0521.
[0279] Slavoff SA, Mitchell AJ, Schwaid AG, Cabili MN, Ma J, Levin JZ, Karger AD, Budnik BA, Rinn JL, Saghatelian A. (2013). Peptidomic discovery of short open reading frame-encoded peptides in human cells. Nat Chem Biol 9: 59-64.
[0280] Slota M. , Lim J.B., Dang Y., Disis M.L. (2011). ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines, 10, pp. 299-306.
[0281] Szczepihska, T., Kalisiak, K., Tomecki, R., Labno, A., Borowski, L.S., Kulinski, T.M., Adamska, D., Kosinska, J., and Dziembowski, A. (2015). DIS3 shapes the RNA polymerase II transcriptome in humans by degrading a variety of unwanted transcripts. Genome Res. 25, 1622-1633. 10.1101 / gr.189597.115.
[0282] Todoerti K, Ronchetti D, Favasuli V, Maura F, Morabito F, Bolli N, Taiana E, Neri A. (2022). DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. Haematologica 107: 921-932.
[0283] Tomecki, R., Drazkowska, K., Kucinski, I., Stodus, K., Szczesny, R.J., Gruchota, J., Owczarek, E.P., Kalisiak, K., and Dziembowski, A. (2014). Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target. Nucleic Acids Res 42, 1270-1290. 10.1093 / nar / gkt930.
[0284] Volders P-J, Anckaert J, Verheggen K, Nuytens J, Martens L, Mestdagh P, Vandesompele J. 2019. LNCipedia 5: towards a reference set of human long non-coding RNAs. Nucleic Acids Res 47: DI 35- D139. Walker BA, Mavrommatis K, Wardell CP, et al. (2018). Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132(6):587-597. Blood 132: 1461.
[0285] Walz, S., Stickel, J.S., Kowalewski, D.J., Schuster, H., Weisel, K., Backert, L., Kahn, S., Nelde, A., Stroh, T., Handel, M., et al. (2015). The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood 126, 1203-1213. 10.1182 / blood-2015-04-640532.
[0286] WeiBbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M, Bargou R, Einsele H, Rosenwald A, Knop S., Leich E. (2015). The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol 169: 57-70.
[0287] White BS, Lane I, O’Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA, Fiala M, King J. et al. (2018). A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8: 35.
[0288] Wright BW, Yi Z, Weissman JS, Chen J. (2022). The dark proteome: translation from noncanonical open reading frames. Trends in Cell Biology 32: 243-258.
Claims
CLAIMS1. A tumor specific peptide, or a fragment thereof, wherein said peptide is between 8 to 30 amino acids in length and:(i) is derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55, 56, 61 and 64- 81, with the proviso that when said translated ORF sequence is SEQ ID NOs: 17, the tumor specific peptide derived from this ORF sequence is other than that of SEQ 37 ; or(ii) comprises, essentially consists of, or consists of a sequence selected from the group consisting of SEQ ID NOs: 18-36, 58, 59, 62, 63 and 82-104.
2. The tumor specific peptide, or a fragment thereof, wherein said peptide:(i) is derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-3, 7, 17 and 64-81, with the proviso that when said translated ORF sequence is SEQ ID NOs: 17, the tumor specific peptide derived from this ORF sequence is other than that of SEQ 37, preferably any of SEQ ID NOs: 1-3, 7 and 17; or(ii) comprises, essentially consists of, or consists of a sequence selected from the group consisting of SEQ ID NOs: 82-104, preferably any of SEQ ID NOs: 96-98, 101 and 102.
3. A combination or a multimeric antigen comprising at least two peptides, wherein said peptides are between 8 to 30 amino acids in length and:(i) are derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-17, 55-57, 61 and 64-81; and / or(ii) comprise, essentially consist of, or consist of a sequence selected from the group consisting of SEQ ID NOs: 18-37, 58-60, 62, 63 and 82-104.
4. The combination or multimeric antigen of claim 3, wherein said peptides:(i) are derived from the translated ORF sequence from long noncoding RNA (IncRNA), wherein said translated ORF sequence is selected from any of SEQ ID NOs: 1-3, 7, 17 and 64-81, preferably any of SEQ ID NOs: 1-3, 7 and 17; and / or(ii) comprise, essentially consist of, or consist of a sequence selected from the group consisting of SEQ ID NOs: 82-104, preferably SEQ ID NOs: 96-98, 101 and 102.
5. The combination or multimeric antigen of claim 3 or 4, wherein it comprises at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 peptides.
6. A recombinant vector comprising a nucleic acid coding for a peptide of any one of claims 1 to 2 or for the combination or multimeric antigen of any one of claims 3 to 5, wherein the nucleic acid is optionally linked to a regulatory region.
7. A host cell comprising a recombinant vector of claim 6.
8. An antibody or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds a peptide as defined in any one of claims 1 to 4; or a nucleic acid coding for such antibody, TCR or CAR; or a vector comprising the nucleic acid coding for such antibody, TCR or CAR.
9. A recombinant immune cell that specifically binds to one or more peptides as defined in any one of claims 1 to 4; or comprises a TCR or CAR of claim 8, or a nucleic acid coding for such TCR or CAR or a vector comprising the nucleic acid coding for such TCR or CAR.
10. A pharmaceutical composition comprising a peptide of any one of claims 1 to 2, a combination or a multimeric antigen of any one of claims 3 to 5, a nucleic acid coding for one or more peptides as defined in any one of claims 1 to 4, a vector of claim 6, a cell of claim 7, an antibody, TCR, CAR, nucleic acid or vector of claim 8, or a recombinant immune cell of claim 9.
11. The composition of claim 10, further comprising another therapeutic agent.
12. The composition of claim 10 or 11, which is a vaccine or immunogenic composition, capable of inducing a specific T-cell immune response.
13. The peptide of any one of claims 1 to 2, the combination or multimeric antigen of any one of claims 3 to 5, a nucleic acid coding for one or more peptides as defined in any one of claims 1 to 4, the vector of claim 6, the cell of claim 7, the antibody, TCR, CAR, nucleic acid or vector of claim 8, the immunecell of claim 9, or the composition of any one of claim 10 to 12, for use in the treatment of a cancer or in the prevention of cancer relapse.
14. The peptide, nucleic acid, vector, cell, combination, multimeric antigen, antibody, TCR, CAR, immune cell or composition of claim 13, wherein the cancer is selected from blood cancer (such as multiple myeloma, acute myeloid leukaemia, chronic myelomonocytic leukaemia, chronic lymphocytic leukaemia, small lymphocytic lymphoma, plasma cell leukemia, mantle cell lymphoma, B-cell lymphoblastic leukemia / lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma), glioblastoma (such as conventional glioblastoma multiforme), glioma (such as high-grade glioma), anaplastic astrocytoma, ovarian cancer (such as high grade ovarian serous adenocarcinoma), uterine cancer (such as uterine corpus leiomyosarcoma), breast cancer (such as invasive breast carcinoma, breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast invasive lobular carcinoma), prostate adenocarcinoma, skin cancer (such as melanoma, superficial spreading melanoma, cutaneous melanoma, acral lentiginous melanoma, Merkel cell carcinoma), lung cancer (such as nonsmall cell lung carcinoma, lung adenocarcinoma, small cell lung carcinoma), leiomyosarcoma, neuroendocrine tumor, neuroendocrine carcinoma, hepatocellular carcinoma, bladder urothelial carcinoma, gastrointestinal stromal tumor and small intestinal neuroendocrine tumor, and in particular multiple myeloma characterized by DIS3 gene mutation or misexpression.
15. The immune cell of claim 9, which is preferably selected from a group consisting of a T cell, CD4+ T cell, CD8+ T cell, B cell, NK cell, NKT cell, monocyte and dendritic cell, for use in cell therapy of cancer.
Citation Information
Patent Citations
T cell epitopes useful in a hepatitis c virus vaccine and as diagnostic tools and methods for identifying same
WO2005042698A2
Method for predicting new antigen derived from non-coding region by integrating multiple omics data
CN113160884A
Use of long non-coding RNA for the diagnosis of prostate cancer
WO2020084035A1
Cited By
Tumor specific antigens and uses thereof for the treatment of pancreatic cancer
WO2026219858A2
